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6Abstract 
Background: Randomized trials and observational studies have consistently shown 
that maternal intake of folic acid supplements before and early in pregnancy reduces 
the risk of neural tube defects in infants. These reports constitute the basis for 
recommending fertile women to use folic acid supplements before and during early 
pregnancy and for introducing food fortification programs with folic acid in numerous 
countries. Furthermore, increasing evidence suggests that prenatal use of vitamins 
including folic acid may also have a protective effect on other adverse pregnancy 
outcomes and complications as well. 
Objectives: In Norway, periconceptional folic acid supplement use is low, despite 
official recommendations and information campaigns to fertile women. This thesis 
aimed to examine the patterns of folic acid supplement use in Norwegian pregnant 
women and to identify important predictors of periconceptional use 1 month before 
pregnancy and throughout the first 3 months of pregnancy. We also tested whether 
various folate indicators, including prenatal folic acid supplement use, were 
associated with placental abruption and infant birth size. These outcomes have been 
linked to folate in previous studies, but results are inconsistent, possibly due to small 
sample sizes and methodological limitations. 
Materials: For the purpose of this thesis, we used observational data from two well-
established data bases: the Medical Birth Registry of Norway (MBRN) and the 
Norwegian Mother and Child Cohort Study (MoBa). MBRN is a national health 
registry in which registration of all live births and stillbirths in Norway has been 
compulsory since 1967 (50,000-60,000 births per year), whereas MoBa is a 
population-based prospective study of Norwegian pregnant women which includes 
more than 100,000 pregnancies between 1999 and 2008. 
Results: Our first paper (based on MoBa) showed that 71.6 percent of the MoBa 
participants in 2000-2003 had taken folic acid-containing supplements at some time 
7before or during pregnancy. Of these, more than 70 percent had started use after 
becoming pregnant, the majority during the first and second month of pregnancy. 
Only 10.2 percent of the participating women had used folic acid-containing 
supplements regularly from 1 month before pregnancy throughout the 3 first months 
of pregnancy. Women who had used folic acid supplements regularly during the 
periconceptional period were more likely to be older, to be married or living together, 
to be non-smokers, to have higher incomes, to have higher education, to have lower
parity, to have planned their pregnancy, and to have received fertility treatments. 
Demographic and socioeconomic factors were the strongest predictors. 
Our second paper (based on MoBa) showed that food folate intake, supplemental folic 
acid use, total dietary folate intake, and maternal plasma folate and homocysteine 
concentrations were not significantly associated with gestational age, infant birth 
weight, head circumference, crown-heel length, or small for gestational age (SGA). 
Consistent with previous studies, infant birth size was strongly predicted by maternal 
smoking (adjusted odds ratio (OR) for SGA = 2.3; 95 percent confidence interval 
(CI): 1.6, 3.3). 
Our third paper (based on MBRN) showed that intake of folic acid and other vitamin 
supplements before and during pregnancy statistically significantly reduced the risk 
for placental abruption by up to 30 percent. Associations between vitamin supplement 
use and placental abruption were strongest for women using both folic acid and 
multivitamin supplements (adjusted OR = 0.68; 95 percent CI: 0.56, 0.83), followed 
by multivitamins alone (adjusted OR = 0.72; 95 percent CI: 0.57, 0.91) and folic acid 
alone (adjusted OR = 0.81; 95 percent CI: 0.68, 0.98). 
Because the response rate of MoBa is low (43 percent), there is concern as to which 
extent the results of MoBa are valid for the total Norwegian population. To evaluate 
potential bias due to self-selection in MoBa, our fourth paper aimed to study 
differences in prevalence estimates and association measures between study 
participants and all women giving birth in Norway, using data from the MBRN. We 
8found no bias in 8 studied exposure-outcome associations, even though several 
exposures and outcomes were overrepresented or underrepresented in MoBa. 
Conclusions: Most women started folic acid supplementation too late with respect to 
the prevention of NTDs. Demographic and socioeconomic factors were the strongest 
predictors for periconceptional folic acid use 1 month before pregnancy throughout 
the 3 first months of pregnancy. This thesis further supports the old hypothesis that 
folate deficiency can be involved in development of placental abruption. Maternal 
intake and status of folate during second trimester appeared not to be associated with 
infant birth size, possibly due to the low number of individuals with low folate status 
in MoBa. 
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1. Introduction 
1.1 Background 
Folate is a water-soluble B-vitamin that occurs naturally in foods (1). It is essential for 
DNA synthesis and normal cell division in humans (2). Folate is also involved in the 
metabolism of homocysteine and helps maintain normal levels of this amino acid (3). 
Overt deficiency of folate may cause a variety of health problems, like megaloblastic 
anemia (4), neurological disorders (5), and hyperhomocysteinemia (6). A chemically 
stable synthetic form of folate, folic acid, is used in dietary supplements and fortified 
foods. 
During the last 20 years, folate has attracted much scientific and public health interest 
due to its role in neural tube defects (NTDs). In the early 1990s, 2 large randomized 
clinical trials demonstrated that daily use of folic acid supplements before and during 
early pregnancy can prevent as much as 70 percent of NTDs (7, 8). Although the 
prevention mechanisms of folate are unknown, these trials constitute the basis for 
recommending fertile women in numerous countries to use folic acid supplements 
before and during early pregnancy (9). Several countries have, in addition, introduced 
mandatory fortification of staple foods (usually flour) with folic acid to increase 
intake of this B-vitamin. 
Despite recommendations and public health campaigns, folic acid supplement use and 
dietary intake of folate before and during early pregnancy is still low in Norway and 
other countries (10). Explanations for this may be that a large proportion of women do 
not plan their pregnancy, and of those who do plan pregnancy, many are still unaware 
of the benefits and recommended timing of folic acid supplement use (9, 10). To 
improve folate intake among fertile women, we thus need to increase awareness and 
knowledge of folate, both in the public and among health care professionals. In order 
to do this, both existing and future epidemiologic studies are needed. 
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Several studies have suggested that the use of folic acid supplements before and 
during pregnancy may also prevent other birth defects and adverse pregnancy 
outcomes in addition to NTDs (11). However, results are not conclusive. Hence, there 
is a need for extensive epidemiologic research on maternal folate status and other 
pregnancy outcomes and complications as well. If folate can reduce the risk of several 
adverse outcomes, this would provide yet another reason for more promotion of folic 
acid supplement use and dietary folate intake among fertile women. 
1.2 Folate 
Before reviewing the literature of folic acid supplement use and its relation to 
pregnancy outcomes, some historical and biochemical background of folate will be 
provided in this section. In addition, I will introduce some basic concepts that will be 
used throughout the thesis. 
The discovery of folate 
The first observation that led to the identification of folate as an important nutrient 
was done by Lucy Wills in 1931 (12). Through studies of pregnant women in 
Bombay, India, she found that a yeast extract could effectively treat macrocytic 
anemia, which was a common pregnancy complication. Wills and her group further 
demonstrated that this type of anemia could be produced in monkeys fed by the same 
diets as the women in Bombay, and that oral administration of yeast or liver extract 
could cure anemia in both monkeys and human patients (13). 
Like Wills and colleagues had demonstrated in monkeys, several other researchers 
reported that anemia could be produced in monkeys and chickens by feeding them 
deficient and purified diets (1). They further found that the anemia appeared to 
respond positively to dietary supplement of the brewer's yeasts, as well as liver 
extract, alfalfa and wheat bran. These protective factors were named vitamin M, 
vitamin Bc, factor U and factor R, but the corrective substance was not identified. 
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In 1940, Snell and Peterson, 2 microbiologists, reported the existence of an 
unidentified water-soluble factor that was necessary for the growth of Lactobacillus 
casei (14). This factor, which became known as the L. casei factor, was present in 
both yeast and liver. In 1941, Snell's group further reported that they had obtained a 
nearly pure form of an acid that promoted the growth of Lactobacillus casei (15). This 
acid was obtained from spinach leaves and stimulated growth of Lactobacillus casei 
under the same conditions as the L. casei factor. Because this acid was found in most 
green leaves, they named the factor by virtue of its sources, folic acid, from the Latin 
word folium for leaf. 
During the early 1940s it was not clear whether folic acid and the anti-anemic factors 
in liver and yeast were related. However, in 1941, Robert Stokstad and his group 
managed to isolate pteroylglutamic acid from liver (16). They further managed to 
synthesize the compound in 1945 (17). Shortly thereafter, pteroylmonoglutamic acid 
was found to be the substance that had been identified in liver as vitamin M, vitamin 
Bc, factor U, and the liver L. casei factor. Furthermore, the yeast derived L. casei 
factor was found to be the diglutamyl derivative of pteroylglutamic acid (1). These 
and other derivatives became generically known as folic acid or folate. 
Forms of folate  
Folate occurs in different chemical forms distinguished by their oxidation state and 
their type of one-carbon substitution (18). The original term, folic acid, usually refers 
to the fully oxidized form of folate, which has no biological function of its own. This 
is the chemically stable synthetic form of folate used in vitamin supplements and 
fortified foods and consists of an aromatic pteredine ring, attached to a 
paraminobenzoic acid conjugated to one L-glutamic acid residue (18, 19). 
Biologically active folate usually differs from folic acid in 3 respects: (i) reduction to 
di- or tetrahydro forms of the pteridine ring, (ii) additional single-carbon units at the 
N5 and N10 position, and (iii) additional number of glutamate chains. Folate in 
human tissues is found as polyglutamate derivatives, whereas folate in human blood 
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and urine is found as monoglutamate derivatives (18). The main circulating form of 
folate is the monoglutamate 5-methyltetrahydrofolate (THF) (18, 19). About half of 
the total body folate content is stored in the liver (18). 
Folate absorption 
Rich sources of natural-occurring folates are liver, yeast, green leafy vegetables, and 
cereal products, but high levels are also found in fruits and dairy products (1, 20, 21). 
Most of the natural folates consumed in foods are polyglutamates, predominantly as 
5-methylTHF and 10-formylTHF (18, 19). Before absorption across the intestinal 
mucosa can take place, the polyglutamate form needs to be hydrolyzed to the folate 
monoglutamate form in the gut lumen. This is done by the folate deconjugase, a brush 
border enzyme in the jejunum (18, 19). Because synthetic folic acid already exists as a 
monoglutamate, it may directly be transported through the intestinal brush border 
without this enzymatic conversion. For this reason the bioavailability in humans is 
considered higher for synthetic folic acid than naturally occurring folate (20). Before 
passing into the blood circulation, folic acid and other folate forms that are not 
already in the 5-methylTHF from need to be reduced and methylated to form 5-
methylTHF. This is done by the enzyme dihydrofolatereductase during transit through 
the intestinal mucosa (18). After passing into the circulating blood, 5-methylTHF 
enters a cell, during which an enzyme adds a chain of polyglutamate residues. The 
polyglutamation is necessary in order to retain folate within the cell. 
Folate metabolism 
Folate participates in 2 different metabolic cycles within the cell, i.e. one involving 
the synthesis of DNA and the other the supply of methyl groups for methylation 
reactions (18, 22). In these cycles, folate undergoes a number of metabolic changes, in 
which the fully reduced form of folate, THF, serves as an acceptor or donor of a one-
carbon unit, reactions commonly referred to as the folate-dependent one-carbon 
metabolism. 
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Nucleotide metabolism 
Folate is involved in the synthesis of DNA by having an essential role in the synthesis 
of the pyrimidine nucleoside, thymidine, and of purines (18, 22). In the synthesis of 
thymidine, the folate intermediate 5,10-methyleneTHF can directly donate its one-
carbon unit in the thymidylate synthase reaction, which converts deoxyuridine 
monophosphate (dUMP) into deoxythymidine monophosphate (dTMP). In the 
synthesis of purines, folate-linked one-carbon units are incorporated into the C2 and 
C8 of purines via 10-formylTHF. During periods of rapid cell division and growth 
such as infancy and pregnancy, sufficient supply of folate to cells is critical to 
maintain normal cell division. 
Methylation reactions 
Folate is also needed in the metabolism of homocysteine and methionine (23). 
Homocysteine is an intermediate product of methionine metabolism and is itself 
metabolized by 2 pathways: the re-methylation pathway which regenerates 
methionine, and the transsulfuration pathway, which converts homocysteine into 
cysteine. The remethylation pathway is comprised of 2 intersecting biochemical 
pathways, one involving 5-methylTHF and vitamin B12, the other involving betaine 
(23). Methionine in turn can be utilized to produce S-adenosylmethionine (SAM), 
which is the primary methyl group donor used in many biological methylation 
reactions, including the methylation of DNA and RNA (23). Because of the role of 
folate in the remethylation of homocysteine to methionine, deficiency of folate may 
contribute to impaired DNA methylation and to accumulation of homocysteine, the 
latter associated with cardiovascular disease and other chronic diseases (3). 
Interrelations of B-vitamins 
The utilization of folate as methyl donor depends on several other B-vitamins. 
Vitamin B2 is the cofactor for methylenetetrahydrofolate reductase (MTHFR), the 
enzyme that reduces 5,10-methyleneTHF to 5-methylTHF (24). Vitamin B12 is 
required by the enzyme, methionine synthase, involved in the conversion of 
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homocysteine to methionine (23). In addition, vitamin B6 is involved in the synthesis 
of 5,10-methyleneTHF from THF (18). Hence, in order to ensure maximal utilization 
of folate as a methyl donor, adequate intake of vitamin B12, B6 and B2 is also 
important. Blood folate and vitamin B12 are strongly associated with homocysteine, 
and supplemental folic acid and vitamin B12 has been used in homocysteine lowering 
therapy in individuals with elevated levels of this amino acid (25). 
Folate status  
The main cause of low folate status in humans is low intake of folate from foods. Low 
folate status can also occur due to malabsorption, which is often recognized in 
alcoholics (26) and individuals with intestinal and gastric diseases, such as celiac 
disease (27). Furthermore, deficiency of other micronutrients, such as zinc (28) and 
iron (29) are associated with impaired food folate utilization. 
Folate requirements are increased in periods during rapid cell division and growth. 
Several studies have reported that women with normal pregnancies have more 
circulating folate before and during early pregnancy than folate concentrations after 
and late during pregnancy (30-32). Furthermore, studies have reported that women 
who have recently undergone a viable pregnancy may become folate deplete in the 
next pregnancy, especially if the inter-pregnancy interval is short (33). Folate status is 
likely to deteriorate in multiple pregnancies. 
Folate status is also affected by particular defects or polymorphisms in the genes 
encoding for folate-dependent enzymes. Most important polymorphisms is C-to-T 
substitution (677C->T polymorphism) that occurs at locus 677 of the MTHFR gene 
(24). The TT genotype reduces the enzyme activity and impairs the conversion of 
5,10-metyleneTHF to 5-methylTHF, which in turn is used in the conversion of 
homocysteine to methionine. 
Studies have shown that whole blood folate varies according to assay format and the 
common MTHFR 677C->T polymorphism (34). The radioassay measures higher 
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folate concentrations in subjects with TT compared to CC genotype, while the 
opposite is found when folate is measured with the microbiological assay (35). This 
has been explained by a larger proportion of the total cellular folate as formylated 
forms of folate in subjects with the TT genotype (36). Formylated folate species may 
be overestimated by the folate binding protein assay, because they have higher affinity 
than 5-methylTHF for the binder (37). 
Several drugs can interfere with folate status. Methotrexate is an antifolate drug used 
in the treatment of cancer and rheumatoid arthritis. It inhibits the production of the 
active form of THF from the inactive form dihydrofolate, resulting in reduced DNA 
synthesis and cell division (38). Furthermore, individuals using some antiepileptic 
drugs (AEDs), especially phenytoin and carbamazepine, are at particular high risk of 
folate deficiency (39). Possible mechanisms by which these drugs interfere with folate 
status include reduced absorption, increased folate metabolism in the liver and altered 
enzyme activity (40). 
1.3 Epidemiology 
In this section, I will briefly review the literature of folate and its relation to NTD, 
placental abruption and infant birth size. I will point to some limitations that should 
be considered in future studies of placental abruption and infant birth size. 
Early works on folate 
The first report that addressed the importance of folate in reproductive health was 
published by Bryan Hibbard in 1964 (41). He assessed folate status as urinary 
excretion of formiminoglutamic acid (FIGLU) in 1484 low-income obstetric patients 
from Liverpool, United Kingdom. Abnormal FIGLU excretion was not only related to 
megaloblastic anemia, but also to placental abruption and spontaneous abortion. He 
also showed that abnormal FIGLU excretion was related to adverse outcomes in 
previous pregnancies, including infant low birth weight, congenital malformations,
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and perinatal mortality. He hypothesized that increased adverse pregnancy outcomes 
in many cases reflected poor folate status due to several factors, like a "demand and 
supply" problem during pregnancy, a less efficient absorption during pregnancy, and a 
defective utilization of folate due to certain drugs (42). Hibbard later showed that 
poor folate status was particularly associated with 3 outcomes: placental abruption, 
congenital malformations, and small for gestational age (SGA) (43). 
Neural tube defects (NTDs) 
Shortly after Bryan Hibbard's report in 1964, Elisabeth Hibbard and Richard Smithells 
suggested that folate deficiency in pregnancy may be related to central nervous system 
malformations (44). Smithells and his group started a series of observational and 
intervention studies demonstrating that vitamins, including folate, reduced the risk of 
NTDs (45-47), which was a common malformation (4.5 per 1000 births) in the United 
Kingdom in the 1970s and 1980s (48). In a study from 1983 (45), almost 1000 women 
with previous NTD pregnancies were enrolled in a non-randomized trial and assigned
0.36 mg folic acid plus multivitamins from 2 months before conception and 
throughout the first trimester. The overall NTD recurrence rates were 0.7 percent for 
454 fully supplemented mothers and 4.7 percent for 519 non-supplemented mothers, a 
difference that was statistically significant (45). At the same time, several randomized 
trials were conducted by others, but findings yielded insignificant results, possibly 
due to the limited number of subjects (49). Unfortunately, Smithells and his group 
were not permitted by their institution to perform a randomized trial, and for that 
reason their findings did not lead to any public health action (50). 
The proposed role of folic acid in the prevention of first occurrence and recurrence 
NTDs was eventually confirmed in the early 1990s in 2 large randomized trials. In 
1991, the Medical Research Council (MRC) in United Kingdom conducted a 
randomized multicenter study of folic acid supplement use among women with a 
previously affected NTD infant. This study demonstrated that women who had been 
given folic acid supplements of 4 mg from 1 month before pregnancy throughout the 
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first pregnancy trimester were associated with a 72 percent statistically significant risk 
reduction of recurrent NTDs, relative to those who were assigned placebo (7). Other 
vitamins showed no significant protective effect. In 1992, Czeizel et al conducted a 
large randomized trial in Hungary of multivitamin use among women with no 
previous NTD infants (8). Women were assigned a supplement of 0.8 mg folic acid 
and other nutrients from 1 month before pregnancy and through the second missed 
menstrual period. No NTD cases occurred in 2104 supplemented women, compared 
with 6 cases among 2052 non-supplemented women (P <0.029). 
In a case-control study in the Unites States and Canada in 1993, Werler et al (51) 
showed that a dose of 400 µg of folic acid contained in multivitamins was found to
reduce significantly the risk of NTDs by approximately 60 percent. The protective 
effect appeared to be confined to daily use in the periconceptional period; no 
appreciable reductions in risk were observed for women who began supplementation 
after the first missed menstrual period. In a community-based intervention study in 
China in 1999, Berry et al (52) further demonstrated that a dose of 400 µg folic acid 
alone during the periconceptional period could prevent up to 80 percent of NTDs in a 
high prevalence area (5 per 1000 births) in North China and 40 percent in a low 
prevalence area (1 per 1000 births) in South China.
There has been a considerable interest in discovering the mechanisms by which folate 
can prevent NTDs. Since folate plays an essential part in the methylation of 
homocysteine to methionine, both elevated homocysteine (22, 53) and MTHFR TT 
genotype of both mother and child (24) have been proposed. The mechanisms remain 
uncertain, however. Regarding the MTHFR TT variant, it may explain only a fraction 
of NTDs prevented. In Italia, for instance, the TT variant is common in the 
population, although the prevalence of NTD occurrence is low (50, 54). Recently, it 
has been suggested that NTDs may be related to auto-antibodies against folate 
receptors (55). This finding was not verified in a study in Ireland in 2009 (56), 
demonstrating the difficulty in establishing a specific mechanism of folate in NTD. 
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Placental abruption 
After Hibbard's observation of an association between excessive FIGLU excretion 
and placental abruption in 1964 (41), many other studies, including a randomized 
trial, evaluated the association of folate deficiency or folic acid supplementation with 
this pregnancy complication (43, 57-60). Unfortunately, results from these studies 
were diverging and few researchers pursued the hypothesis further into the 1980s. 
In the 1990s and early 2000s, several observational studies showed a consistent 
relation between homocysteine and placental abruption (61-64). Furthermore, a meta 
analysis in 1999 showed that both folate deficiency and elevated homocysteine was 
associated with placental abruption (65). Consequently, many researchers 
hypothesized that elevated homocysteine in some cases may be the underlying cause 
of some abruptions: homocysteine can cause vascular damage, which may result in 
blood clots behind the placenta (66). However, since plasma homocysteine analysis in 
these studies was made after the onset of abruptions, a specific function of 
homocysteine in placental abruption is uncertain (11). More recently, several studies 
have been undertaken to explore the possible association between placental abruption 
and several maternal polymorphisms of enzyme genes in the folate metabolism, 
including MTHFR (67-72). However, also these results are inconsistent, 
demonstrating the difficulty in establishing a specific role of folate in abruption. 
A major limitation of previous epidemiologic studies is the small sample size used. 
The prevalence of placental abruption occurs in about 0.5 to 1 percent worldwide 
(73), and clearly large samples are needed to detect a precise effect of various risk 
factors. Furthermore, surprisingly few epidemiologic studies have addressed whether 
supplemental folic acid or multivitamin use during pregnancy can reduce occurrence 
of the complication, even though blood folate, vitamins B12, B6, A and E have been 
associated with reduced risk of placental abruption (62, 64, 74). In paper 3, we tested 
this hypothesis by using data from a large population-based registry in Norway 
(55,000-60,000 births per year), where both folic acid and multivitamin use before 
and during pregnancy, as well as placental abruption, are recorded. 
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Infant birth size 
Hibbard demonstrated that blood folate concentration early in pregnancy was 
associated with the size of the infant at birth (43). This association was mainly found 
for SGA and to a less extent for preterm birth. Although the administration of folic 
acid in pregnancy had been of short duration, he further found that low folate 
concentrations were less common for those who had been given folic acid 
supplements (43). 
Over the years, several large randomized trials have examined the effect of prenatal 
use of vitamins containing folic acid on infant low birth weight (<2500 g), preterm 
birth (<37 weeks gestation), and SGA. While some trials have observed a relation 
with low birth weight or SGA (75, 76), others have shown no significant association 
of folic acid supplementation with these outcomes, neither alone (77, 78) nor in 
combination with other vitamins (79). Also, numerous observational studies have 
examined the relation of prenatal use of folic acid-containing supplements, dietary 
folate intake, and maternal blood folate status, with low birth weight, preterm birth 
and SGA. While some studies have found a relation (80-87), others have not (88-91). 
A Dutch study on several B vitamins measured in blood before and during pregnancy 
in healthy, well-nourished women demonstrated no association between the vitamin 
concentrations and infant birth weight (92). Diverging results are also reported 
regarding elevated homocysteine (61, 80, 88-91, 93), and the evidence of an 
association between maternal and fetal MTHFR polymorphisms and these outcomes 
is not conclusive (11). 
The conflicting results obtained from trials and observational studies may be due to 
methodological issues, such as small population size, lack of control for confounding 
factors, and timing of folate exposures. Nevertheless, in order to draw firm 
conclusions regarding folate and infant birth size, one also should include information 
on several folate exposures (e.g., circulating folate, food folate intake, folic acid 
supplement use) and several birth size parameters, which most studies have not. In 
paper 2, we used a subsample of a large population-based pregnancy cohort in 
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Norway to evaluate the association of various folate indicators with gestational age, 
infant, birth weight, head-circumference, crown-heel length, and SGA. 
1.4 NTD prevention strategies 
In this section, I will focus on the international and national strategies for the 
prevention of NTDs. I will point to some important issues that I think need further 
investigation in Norway and other countries. 
NTD occurrence 
The neural tube is the precursor to the central nervous system. During early 
pregnancy, and within the first 28-30 days of pregnancy, the neural tube gradually 
closes to form the spinal cord and brain (49, 50). Failure of closure results in NTDs, 
of which there are 2 main forms depending on whether the cranial or caudal end of the 
neural tube is involved (49, 50). The most common types of NTDs are: 
• Spina bifida (caudal): The spinal cord is not completely closed. The opening in 
the spine may or may not be covered by a layer of skin. This malformation is 
associated with disabilities later in life. 
• Anencephaly (cranial): The skull and brain is not completely developed. The 
opening is often not covered by bone or skin. This malformation is incompatible 
with life. 
• Encephalocele (cranial): The skull is not completely closed. Parts of the infant's 
brain may come through the opening in the skull. The degree to which they can be 
corrected depends on the size of the encephalocele.
In the European Union, NTDs affect at least 4500 pregnancies each year (48). These 
include live births, stillbirths, and pregnancy terminations after prenatal diagnosis. 
The highest NTD prevalence in Europe is found in United Kingdom and Ireland, 
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where the frequency was 45 per 10,000 births in 1980 and 10 to 15 per 10,000 in the 
1990s (48). In Norway, about 1 in 1000 is affected, corresponding to around 60 cases 
per year, mostly spina bifida and anencephaly (Table 1; Medical Birth Registry of 
Norway (MBRN) Online Birth Statistics: www.fhi.no).
Table 1. Number of NTDs in Norway as registered by MBRN, 2007 
NTDs  
Total 
(n = 59,632) 
Live births 
(n = 58,969) 
Stillbirths 
(n = 404) 
Induced 
abortions 
(n = 259) 
      
All  61 16 1 44 
Anencephaly   18 0 1 17 
Spina bifida  35 13 0 22 
Encephalocele  8 3 0 5 
Recommendations 
The MRC and Hungarian randomized trials in 1991 and 1992 laid the ground for a 
major public health opportunity to facilitate NTD prevention. Today, these reports 
constitute the basis for recommending fertile women to use folic acid supplements 
before and during early pregnancy and for introducing food fortification programs 
with folic acid in numerous countries (9). 
The first recommendation in Norway on folate use and pregnancy was issued by the 
Norwegian Board of Health in 1993 (94). This recommendation stated that women 
with a previous affected infant should been given 4 mg of daily folic acid during the 
periconceptional period to prevent recurrence of a NTD. There was no folic acid 
recommendation for women without a history of NTD, apart from increasing their 
intake of folate from foods. In 1998, a second recommendation of periconceptional 
folic acid use was issued by the Norwegian Nutrition Council (95). This 
recommendation stated that all women who may become pregnant should take a daily 
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folic acid supplement of 400 µg from 1 month before pregnancy throughout the first 
2-3 months of pregnancy to reduce the risk of NTDs. Women with an increased risk 
of delivering a child with NTD (for instance, women with previous affected infant 
and those using AED) were recommended to take higher doses of 4 mg of daily folic 
acid during the periconceptional period. Mandatory food fortification with folic acid 
to increase intake, as implemented in the United States and other countries, has not 
been introduced in Norway (see next section below).
After the folic acid recommendations were issued in Norway in 1998, several public 
health campaigns have been conducted to disseminate the recommendations to fertile 
women (96-98). When the recommendations were launched, a public folder, poster 
and guidelines for health personnel were made (96). Pharmacies were asked to 
distribute the public folders to all persons who were buying contraceptive pills, other 
contraceptive prevention, or folic acid tablets. The message on periconceptional folic 
acid use and NTDs was also advertized in womens' magazines and in various health 
journals for health personnel. In 2002, an official website regarding pregnancy and 
folate was established by the Norwegian Nutrition Council (96). This website is now 
under revision (www.helsedirektoratet.no). 
Despite official recommendations and large public health campaigns, the overall folic 
acid supplement use and dietary intake of folate is still low among Norwegian 
fertile/pregnant women (97, 99, 100). In a study from Oslo in 2003, only 17 percent 
of the participating women reported folic acid supplement use prior to pregnancy. A 
substantially lower percentage (2 percent) was observed by the same authors among 
immigrants. Nevertheless, recent numbers from the MBRN show a marked increase in 
the preconceptional use of folic acid in pregnant women from 5 percent in 1999 to 27 
percent in 2007 (MBRN Online Birth Statistics: www.fhi.no), indicating a growing 
folate interest among fertile women. From 1999 through 2007, however, there has not 
been a reduction in NTDs in Norway (Figure 1; MBRN Online Birth Statistics: 
www.fhi.no). 
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The most important predictors for not taking folic acid supplements 
periconceptionally are unplanned pregnancies, low socioeconomic levels, and young 
age (9). However, also other important determinants of supplement use exist, and 
further investigation of such predictors should be carried out to help design more 
effective intervention programs to improve periconceptional intakes of folic acid in 
Norway and other countries. Also, more information is needed regarding timing of 
folic acid supplement use. Apparently, a substantial portion of women starts folic acid 
supplementation too late with respect to NTD prevention (96), but it is unclear how 
late in pregnancy they start. In paper 1, we took advantage of a large pregnancy cohort 
in Norway to examine both patterns and predictors of folic acid supplement use. 
Figure 1. NTD occurrence by year of birth as registered by MBRN, 1967-
2007. Numbers from January 1999 through 2007 include information on 
pregnancy terminations after prenatal diagnosis. 
Food fortification 
Food fortification refers to the situation in which a country has enriched certain food 
products (usually staple foods) with vitamins and other micronutrients to ensure that 
minimum dietary requirements are met. This can be done either voluntary or 
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mandatory, or both. Mandatory food fortification is usually regulated by law, whereas 
voluntary food fortification is regulated by specific permission from health 
authorities. 
The rationale of fortifying foods with folic acid in many countries is the low 
compliance with folic acid recommendations among pregnant women and that most 
women do not meet the recommended dose of 400 µg folic acid through diets alone. 
In Norway, only voluntary food fortification with folic acid is allowed. However, by 
2009 only few food production companies had taken advantage of this possibility 
(www.mattilsynet.no). Although voluntary food fortification has proven to increase 
maternal blood folate status markedly in some countries (101), the effect on the NTD 
occurrence is still less than expected (9). 
In 1996, the Food and Drug Administration in the Unites States issued regulations 
requiring that grains be fortified by folic acid by January, 1998. The level of folic acid 
was set at 140 µg per 100 g of cereal grain product (9, 102). The average of folic acid 
intake was estimated to increase by 100 µg per day. To meet the recommended daily 
dose of 400 µg/day folic acid, women were recommended to consume additional folic 
acid supplements (9). After legislation in the United States was passed, other 
countries, including Canada and Chile, have introduced mandatory food fortification 
with folic acid (103, 104). In 2007, the number of countries with national regulations 
for mandatory wheat-flour fortification was 54 (105). 
The decision to fortify foods with folic acid by law in Norway has been postponed 
due to concerns regarding potential side-effects of high dose folic acid in certain 
subgroups of the population (96). Particularly, there has been a concern as to whether 
folate may promote the growth of premalignant and malignant lesions in humans 
(106, 107). If this is true, the benefits of mandatory food fortification to prevent 
NTDs probably do not outweigh the risk of cancer in certain groups. 
A comparison of NTD prevalence before and after fortification in the United States 
shows a decline in the prevalence of spina bifida and anencephaly (23 and 11 percent, 
27
respectively) (108). However, NTDs were declining before fortification, suggesting 
that other factors than fortification may play a part. In Ontario, Canada, voluntary and 
mandatory fortification (flour, pasta, and cornmeal) was introduced in 1995 and 1998, 
respectively. During 1995-1999, the NTD occurrence decreased by 48 percent (109). 
In Chile, wheat flour fortification with folic acid has been mandatory since 2000. 
Compared with pre-fortified periods, the prevalence of spina bifida and anencephaly 
in the post-fortified period fell by 51 and 42 percent, respectively (110). 
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2. Objectives 
The present thesis aimed to study folic acid supplement use and its relation to birth 
outcomes in Norwegian pregnant women. All research questions were addressed in 4 
papers using data from the Norwegian Mother and Child Cohort Study (MoBa) and 
the Medical Birth Registry of Norway (MBRN). 
The main research questions were: 
1. To which extent do Norwegian pregnant women follow the recommendations 
regarding periconceptional folic acid supplement use? [Paper 1] 
2. Which maternal factors predict periconceptional folic acid supplement use among 
Norwegian pregnant women? [Paper 1] 
3. Is infant birth size associated with second-trimester folate status in Norwegian 
pregnant women? [Paper 2] 
4. Is periconceptional folic acid and multivitamin supplement use associated with 
placental abruption in Norway? [Paper 3] 
Because the response rate of MoBa is low (43 percent), there is concern as to which 
extent the results of MoBa are valid for the total Norwegian population. This thesis 
therefore also aimed to study the following methodological questions: 
5. Are prevalence estimates of exposure and outcome variables in MoBa different 
from those of all women giving birth in Norway? [Paper 4] 
6. Are exposure-outcome associations in MoBa different from those of all women 
giving birth in Norway? [Paper 4] 
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3. Materials and methods 
3.1 Study populations 
In this section, I give a description of the study populations and the sample selection 
criteria used for each paper in the thesis. 
The Medical Birth Registry of Norway (MBRN)  
MBRN is a national health registry in which registration of all live births and 
stillbirths in Norway has been compulsory since 1967 (111). It was initiated by the 
Directorate of Health with the aims to monitor and identify causes for perinatal 
morbidity and mortality in both mother and child (111, 112). The registry comprises 
extensive medical information on the mother’s health before and during pregnancy, 
on delivery, and on the newborn. The information is collected from hospital records at 
admittance for delivery and from an antenatal form, which the mother brings to the 
birth clinic. All data are further registered in a standardized notification form at the 
time of birth (Appendix 1). The midwife and/or the physician attending the birth are 
responsible for completing the notification form, and sending it to the registry within 
a few weeks after birth. In December 1998, a revised version of the notification form 
was introduced to include new variables (Appendix 1), such as maternal dietary 
supplement intake and smoking. The papers in the present thesis were based on data 
from the revised form only. 
The Norwegian Mother and Child Cohort Study (MoBa) 
MoBa is a population-based prospective study of Norwegian pregnant women that 
includes more than 100,000 pregnancies between 1999 and 2008 (113). The objective 
of the study is to identify genetic and environmental risk factors for various health 
problems in mothers and their children both during pregnancy and in childhood. The 
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cohort was established in Western Norway in 1999 and was gradually expanded to a 
national level during the study period. Women were recruited to the study through a 
postal invitation after they had signed up for the routine ultrasound examination at 
their local hospital (around 18 weeks of gestation). In 2008, 50 hospitals had been 
included in the study. At the ultrasound examination, participating women and their 
partners were asked to donate blood samples (Appendix 2). In addition, after delivery, 
a blood sample was collected from the umbilical cord and a second blood sample was 
taken from the mother. During pregnancy, the mother received 3 questionnaires and 
the father received 1. The mothers were further asked to respond to 4 additional 
questionnaires during early childhood (0-7 years). The present thesis was based on the 
maternal questionnaires 1-3 during pregnancy (Appendix 2) and on the maternal 
blood sample collected around gestational week 18. 
Tracking and linking data 
MoBa uses a database tracking system to register pregnant women and to follow the 
progress of participants through the various phases of the study. Since a woman can 
take part in the survey with several pregnancies, the unit of observation is the 
pregnancy and not the woman. To retrieve registered pregnancy outcomes and other 
pregnancy-related information, participants of MoBa are linked to MBRN by using 
the national identification number (113). MoBa and MBRN are both administered by 
the Norwegian Institute of Public Health in Bergen.
Sample selection criteria 
Paper 1: We included 25,935 MoBa participants with births during the period 2000-
2003. Of these, 23,201 pregnancies (89 percent) had complete information on selected 
follow-up criteria (Table 2). If a woman had several pregnancies during this study 
period, we used only her first pregnancy. We also excluded women who had missing 
information on dietary supplement intake data in the baseline and the follow-up 
questionnaire. The final sample for analyses comprised 22,500 women. 
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Table 2. Inclusion criteria for papers 1 through 4
  Paper 
Inclusion criteria Description 1 2 3 4 
      
Time period Year of birth 2000-
2003 
2002-
2003 
1999-
2004 
2000-
2006 
      
MBRN notification 
form 
Information collected at 
birth 
Yes Yes Yes Yes 
MoBa baseline 
questionnaire 
Prenatal information 
(median 18 weeks) 
Yes Yes   
MoBa food frequency 
questionnaire 
Prenatal information 
(median 18 weeks) 
Yes   
MoBa maternal blood 
samples 
Prenatal information 
(median 18 weeks) 
Yes   
MoBa follow-up 
questionnaire 
Prenatal information 
(median 30 weeks) 
Yes    
      
Initial study sample  Number of subjects with 
all data sources 
23,201 14,838 349,043 398,849
Final study sample Number of subjects 
included in the analysesa
22,500 2934b 280,127 398,849
a Exclusions are described in the text. 
b Random sample of subjects available for retrieval from the MoBa Biobank. 
Paper 2: We analyzed data in a random sample of 3000 MoBa women during the 
period July 1, 2002 - December 31, 2003. Initially, there were 17,588 women with 
registered births during this period. Of these, 14,838 women (84 percent) had 
complete information on selected follow-up criteria, including blood samples (Table 
2). At the time of sampling, only 6723 blood samples had been processed and were 
ready for retrieval from the MoBa Biobank. We randomly selected 3000 of these 
samples. We excluded multiple births and women who had no information on both 
gestational age and infant birth weight, leaving 2934 women for analyses. 
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Paper 3: We analyzed data from MBRN during the period 1999-2004. Initially, there 
were 349,043 infants during this period. We excluded 12,944 infants from multiple 
births and further 55,972 births (16 percent) where information on supplemental 
vitamin use was missing, leaving 280,127 singleton births (representing 226,724 
women) for analyses (Table 2). 
Paper 4: We analyzed data from MBRN during the period 2000-2006. Women who 
agreed to participate in MoBa (n = 73,579) were compared with all women giving 
birth in Norway (n = 398,849). Women who had more than 1 pregnancy during the 
study period and who agreed to MoBa participation in more than 1 of the pregnancies 
were defined as unique participants with each pregnancy. The study had no exclusions 
of subjects (Table 2). 
3.2 Folate indicators 
Information on maternal folate intake and status was obtained from both MBRN and 
MoBa (Table 3). In this section, I provide a brief description of the various folate 
indicators used in the various papers. 
Folic acid supplement use (Paper 1) 
Information on dietary supplement use in MoBa was collected in a baseline and a 
follow-up questionnaire returned by the women around gestational weeks 18 and 30, 
respectively (Appendix 3 and 4). Women who used dietary supplements were asked to 
report in detail which vitamins/minerals they were taking based on the label of their 
supplement container, and when and how often the supplements were taken. Dosage 
was not asked for. A woman was defined as a folic acid user if she reported use of 
supplements containing folic acid more than once a week during a 4-week period 
(Appendix 3 and 4). Periconceptional intake was defined as starting folic acid 
supplement use 1 month before pregnancy and continuing use throughout the first 3 
months of pregnancy (Table 3). 
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Table 3. Folate indicators included in papers 1 through 4
Folate indicator Source Description Categorization 
    
Paper 1    
Folic acid 
supplement use 
MoBa baseline 
and follow-up 
questionnaire 
Use of folic acid supplements 
more than once a week during 
a month 
No, yes 
Periconceptional 
folic acid use 
MoBa baseline 
and follow-up 
questionnaire 
Folic acid use from 1 month 
before pregnancy through the 
first 3 months of pregnancy 
No, yes 
Paper 2    
Folic acid 
supplement use 
MoBa food 
frequency 
questionnaire 
Mean intake during the first 18 
weeks of pregnancy  
0, 1-399, 400 
µg/day 
Food folate 
intake 
MoBa food 
frequency 
questionnaire 
Mean intake during the first 18 
weeks of pregnancy 
Quartiles 
Plasma folate MoBa blood 
sample 
Maternal blood samples 
around 18 weeks of gestation 
Quartiles 
Papers 3 & 4    
Folic acid and 
multivitamin 
supplement use 
MBRN 
notification form 
Regular use before and/or any 
time during pregnancy  
No, yes 
Dietary folate intake (Paper 2) 
Information on dietary food intake and supplement use in MoBa was also collected 
using a semi-quantitative food frequency questionnaire (FFQ). The FFQ consisted of 
263 questions about 255 food items and was designed to capture dietary habits and 
intake of dietary supplements during the first 4-5 months of pregnancy (114, 115). 
The FFQ has been thoroughly validated (116). 
Participants reported their food intake by selecting mean frequencies of intake of each 
food item from never to several times monthly, weekly, or daily (Appendix 5). In 
addition, global questions were asked regarding the weekly/monthly intake of hot 
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meals, fruits and vegetables. If the total number of detailed items deviated from the 
number given in the global question, the global questions were used as scaling factors 
(115). For instance, if a woman reported that she had chicken/turkey for dinner twice 
a week in the global question, but the total number of hot meals with chicken/turkey 
was 3 in the detailed questions, intake of each chicken/turkey item was scaled down 
to a total of 2. In the same way, if the answer to the global question was 3 and the 
total number of chicken/turkey meals was 2, the amount was scaled up. However, the 
total number of hot meals was finally scaled down to a maximum of 365 per year. 
Scaling was also applied to spreads on bread relative to the reported number of bread 
slices. Energy and nutrient intakes (amount/day) were calculated with the use of 
FoodCalc (www.ibt.ku.dk/jesper/foodcalc) and the Norwegian food composition table 
(www.matportalen.no/matvaretabellen). 
Dietary supplement use was reported by participants either from a predefined list of 
the most commonly used supplements or by detailed textual descriptions (Appendix 
6). The frequency of supplement use ranged from never to 7 times per week, and the 
quantity was reported by the number of tablets, capsules, or spoons. The folic acid 
content in the dietary supplements was obtained from a database that included more 
than 1000 different dietary supplements (115). A data program connected to the 
database read all food supplements recorded by the women. The database was 
continuously updated with new supplements throughout the study period. 
In statistical analyses, food folate and total folate intake from both food and 
supplements were analyzed as continuous variables or as relative cut-offs by dividing 
the distribution of folate intake into quartile exposures (Table 3); folic acid 
supplement use was divided into 3 categories: 0, 1-399, and 400 µg/day. 
Plasma folate status (Paper 2) 
Concentrations of plasma folate and total homocysteine were assessed from maternal 
blood samples collected at the time of the routine ultrasound examination at their 
local hospital. The median gestational age for blood sampling was 18 weeks. 
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Blood samples (non-fasting) used for the preparation of plasma were collected into 
ethylenediaminetetraacetic (EDTA) tubes, centrifuged within 30 minutes after 
collection, and placed in the hospitals’ refrigerator (4 °C). They were shipped by mail 
overnight to the Biobank of MoBa. On the day of receipt, which was usually 1-2 days 
after blood donation, EDTA plasma were aliquoted onto polypropylene micro-titre 
plates (300 µL per well, 96 well format), sealed with heat-sealing foil sheets, and 
stored in freezer at -80 °C. A description of the blood sample collection and 
laboratory methods is found elsewhere (117). 
Plasma folate concentration was measured by microbiological assay, using a 
chloramphenicol resistant strain of Lactobacillus casei (118). The assay determines 
biologically active folate species, predominantly 5-methylTHF, and has a coefficient 
of variation that corresponds to 4 percent within day and 5 percent between days, at 
population median (www.bevital.no). The sample handling did not involve addition 
of ascorbic acid. Plasma total homocysteine concentration, which included both free 
and protein-bound fractions of homocysteine, was determined using a mass 
spectrometry method (119). 
In statistical analyses, plasma folate and plasma homocysteine were analyzed as 
continuous variables or as relative cut-offs by dividing the distribution of plasma 
concentrations into quartile exposures (Table 3). 
Vitamin supplement use (Papers 3 and 4) 
Information on vitamin supplement intake in MBRN was collected during 
hospitalization at the time of birth and was recorded into the notification form using 
check boxes. Information on supplement use included questions on regular use of 
folic acid supplements before or during pregnancy and regular use of multivitamin 
supplements before or during pregnancy (Appendix 7). Information on dosage, 
frequency or exact duration of folic acid use was not recorded. Vitamin supplement 
use was classified as use of folic acid and/or multivitamin supplements before or any 
time during pregnancy (Table 3). We also categorized the women by time-period of 
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vitamin use (i.e., both before and during pregnancy, during pregnancy only, and 
before pregnancy only), and by supplement type (i.e., multivitamin alone, folic acid 
alone, and both folic acid and multivitamin). 
3.3 Pregnancy outcomes and complications 
Information on pregnancy outcomes and complications were obtained from the 
MBRN. I here provide a description of the main outcome variables used in the 
various papers (Table 4). 
Gestational age was calculated in completed weeks or days based on second trimester 
ultrasound measurements. If ultrasound measurements were missing (about 2.8 
percent of births), gestational age was based on the date of last reported menstrual 
period. Overall, gestational age information was missing for around 0.8 percent of 
births. Preterm delivery was defined as <37 completed weeks of gestation (Table 4). 
Infant birth weight, head circumference, and crown-heel length were measured by the 
attending health personnel immediately after birth and used as markers of infant birth 
size. Low birth weight was defined as infant birth weight <2500 g (Table 4). 
Infant SGA was used as a crude marker of intrauterine growth, and was constructed 
from national reference weights from gestational weeks 20 through 44, classified as 
infant birth weight below the 10th percentile within strata of infant gender and 
gestational age (120) (Table 4). To be consistent with the reference population, SGA 
was obtained by using gestational age based on the last menstrual period date. 
Placental abruption is defined as the premature separation of a normally situated 
placenta (121). The condition was recorded in MBRN using a check box or open text 
coded according to the International Classification of Diseases, Tenth Revision (ICD-
10). Placental abruption is usually a clinical diagnosis based on prenatal signs and 
symptoms, like antepartum haemorrhage, uterine pain or tenderness, or fetal distress. 
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According to current practice in Norwegian hospitals, the diagnostic criteria are 
extended to include retro-placental impression or blood clot behind the placenta. 
Other categorical outcomes were birth defects (any defect and major defects), 
stillbirth, and neonatal death. All birth defects were recorded using textual 
descriptions and coded according to the ICD-10. Stillbirth was defined as the death of 
an infant before or during delivery. Neonatal death was defined as infant death within 
the first month of life. Preeclampsia and gestational diabetes was recorded using 
check boxes or textual descriptions coded according to ICD-10. Apgar score was 
assessed 5 minutes after delivery. 
Table 4. Pregnancy outcomes for papers 1 through 4
  Paper 
Pregnancy outcome Categorization 1 2 3 4 
      
Gestational agea <37, 37 weeks Yes Yes Yes Yes 
Infant birth weighta <2500, 2500 g  Yes  Yes 
Head circumferencea   Yes  Yes 
Crown-heel lengtha   Yes  Yes 
Infant SGA <10th, 10th percentile  Yes   
Placental abruption No, yes   Yes Yes 
Preeclampsia No, yes   Yes Yes 
Gestational diabetes No, yes    Yes 
Birth defects No, yes    Yes 
Stillbirth No, yes    Yes 
Neonatal death No, yes    Yes 
Apgar scorea     Yes 
a Continuous variables. 
38
3.4 Other relevant variables 
Covariates were abstracted from both MoBa questionnaires and MBRN. Inclusion of 
covariates and potential confounders in statistical models is discussed later in Chapter 
5.2. All variables are shown in Appendix 8 and described in the papers. Notably, 
maternal smoking in MoBa was assessed both from self-reported data and from 
cotinine in blood plasma. Cotinine is the primary metabolite of nicotine and is 
considered a sensitive marker of tobacco exposure (122). Plasma cotinine was 
determined by using a mass spectrometry method (119), and a woman was considered 
as an active smoker if her cotinine concentration was 85 nmol/L (122, 123). 
3.5 Statistical analyses 
All statistical analyses were performed using SAS (Statistical Analysis System) 
version 9.2 software for Windows (SAS Institute, Inc., Cary, North Carolina) and R 
version 2.8.1 (www.r-project.org/). All P values were 2-sided, and values <0.05 were 
considered statistically significant. 
Data were described as relative frequencies or means together with a variability 
measure, such as standard error, standard deviation, or confidence interval (CI). 
Potential confounding factors and relevant effect modification variables were chosen 
a priori based on information in previous literature. Inclusions of confounders and 
interaction terms in statistical models are discussed in more detail in Chapter 5.2 and 
5.4, respectively. 
Associations between dichotomous outcomes and exposures were assessed using 
simple and multiple log-binomial regression models. In these models, relative risk 
(RR) and odds ratio (OR) and their corresponding 95 percent CIs were obtained using 
a log-link or logit-link function, respectively. We estimated OR when the prevalence 
of the study outcome was low (papers 2, 3, and 4) and RR when the prevalence of the 
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study outcome was frequent (paper 1). The latter was done because ORs for common 
conditions are not good approximations of RR (124).
Paper 1: All analyses were adjusted for maternal age, marital status, maternal 
education, parity, and year of birth. Prevalence of folic acid use was adjusted by using 
a direct standardization method. This was performed in a 3-stage operation, 
thoroughly described in the paper. If a woman participated with several pregnancies, 
only the first was included in the analyses. Predictors were assessed by using log-link 
binomial regression and RR. A test for linear trend or group difference in prevalence 
of supplement use over the levels of a predictor was calculated by incorporating the 
predictor as a linear variable or as a categorized variable in the models (Wald test), 
respectively. This paper also used a log-link binomial regression model for repeated 
measures to examine a group-by-time effect on supplement use from 2 months before 
pregnancy through the eighth month of pregnancy. That is, we tested whether the 
patterns of folic acid use were different for, for example, epileptics and non-
epileptics. 
Paper 2: All analyses were adjusted for maternal age, marital status, maternal 
education, parity, prepregnancy body mass index (BMI), and plasma cotinine. 
Additional adjustments were done for specific analyses. Food folate and plasma folate 
values were divided into quartiles, whereas folic acid supplement use was divided 
into 3 categories: 0, 1-399, 400 µg/day. Associations were assessed by using linear 
regression models for continuous outcomes (i.e., gestational age, infant birth weight, 
head-circumference, and crown-heel length) and logistic regression models for 
dichotomous outcomes (i.e., SGA). A test for linear trend or group difference in 
means or prevalence over the exposure levels was calculated by incorporating the 
exposure as a linear variable or as a categorized variable in the models (Wald test), 
respectively. Correlation between pairs of measures was assessed by Spearman 
correlation coefficient. A dose-response association between continuous exposure 
data and SGA was examined using generalized additive logistic regression models 
40
(GAMs) (125). GAMs are readily used to explore and visualize dose-response 
relations, especially when relations are non-linear. 
Paper 3: All analyses were adjusted for maternal age, marital status, parity, self-
reported smoking, pregestational diabetes, and chronic hypertension. Associations of 
folic acid supplement use and multivitamin use with placental abruption were 
assessed using logistic regression models. Because analyses included women with 
several pregnancies during the study period 1999-2004, the potential intra-individual 
correlation between 2 or more pregnancies from the same woman was taken into 
account by using generalized estimating equations for logistic regression models 
(126). We also used Cox regression analysis with a binary time-varying covariate 
(gestational age <37weeks or 37 weeks) to test whether hazard ratios for vitamin use 
were significantly stronger for preterm abruption than for term abruption. Effect 
modification of the vitamin - abruption association by smoking and preeclampsia was 
explored by stratification and by including the relevant interaction term in regression 
models, evaluated by likelihood ratio tests. 
Paper 4: Bias in prevalence of 23 exposure and outcome variables was measured as 
the ratio of relative frequencies, whereas bias in exposure-outcome associations of 8 
selected relations was measured as the ratio of ORs. Bias in continuous variables was 
measured by calculating the difference in means. Women who had more than 1 
pregnancy during the study period and who agreed to MoBa participation in more 
than 1 of the pregnancies were defined as unique participants with each pregnancy. 
Logistic regression analyses were performed with adjustment for maternal age, 
marital status, parity, and self-reported smoking at end of pregnancy. To quantify the 
uncertainty of the ratio of adjusted ORs, we computed 95 percent CIs, with correction 
for the inter-dependency between MoBa participants and the total population. This 
was achieved using a nonparametric bootstrap method (127), thoroughly described in 
the paper. The nonparametric bootstrap method was also used to obtain corrected CIs 
for ratios of relative frequencies and differences in means. 
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3.6 Ethical approval 
Informed consent was obtained from each participant before inclusion in the MoBa 
study. All studies were approved by the Regional Committee for Medical and Health 
Research Ethics and by the Norwegian Data Inspectorate. 
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4. Discussion of specific results 
In this section, main results of papers 1 through 4 are summarized, discussed, and 
compared with results of previous studies. 
4.1 Patterns of folic acid supplement use 
In Norway, women who may become pregnant are recommended to take 400 µg folic 
acid daily from 1 month before pregnancy through the first 2-3 months of pregnancy 
(95). The recommendations for folic acid supplement use are intended to prevent 
spina bifida and related NTDs during early pregnancy. 
In paper 1, we examined the patterns and predictors of maternal supplemental folic 
acid use from 2 months before pregnancy through the eighth month of pregnancy. A 
woman was defined as a folic acid user if she reported use of supplements containing 
folic acid more than once a week during a 4-week period. In Norway, the usual 
prenatal folic acid tablets contain 400 µg, whereas most multivitamin tablets include 
200-400 µg folic acid. The study was based on 22,500 pregnant women in MoBa in 
2000-2003, who had returned 2 self-administered questionnaires around gestational 
weeks 18 and 30, and who were registered with births in MBRN. 
Our study showed that 16,116 of the participants (71.6 percent) had taken folic acid-
containing supplements at some time before or during pregnancy. Of these, more than 
70 percent had started use after becoming pregnant, the majority during the first and 
second month of pregnancy. Only 2303 women (10.2 percent) had used folic acid-
containing supplements regularly from 1 month before pregnancy throughout the 3 
first months of pregnancy. Of these, 81 percent had used supplements containing folic 
acid daily. Overall, 8 of 10 women reported that they had planned their pregnancy. 
A low prevalence of periconceptional folic acid supplement use during 2000-2003 
was also seen in MBRN (128) and in a study of pregnant women in Oslo (99), and is 
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consistent with a Norwegian survey of fertile women in 2000, which showed that only 
8.5 percent of the women knew that the critical period for folic acid supplement to 
reduce the risk of neural tube defect is before and early in pregnancy (97). A low 
prevalence of folic acid supplement also agrees with reports from other countries 
where recommendations have been issued (10, 129). In the Danish National Birth 
Cohort, full compliance with recommendations (>80 percent of 400 µg/day from 4 
weeks before conception until the 6 first weeks of pregnancy) was reported to be 14 
percent during 2000-2002 (130), which is comparable to our data. 
Since the folic acid supplement recommendations were issued in 1998, the use of 
folic acid-containing supplements before and during early pregnancy has increased 
substantially in Norway (Table 5), indicating that folic acid promotion among fertile 
women is efficient, at least to some degree. In 2006, the prevalence of 
periconceptional folic acid use in MoBa was at the same level as that reported in the 
United States, Netherlands, and Canada (131-134). In the United States, folic acid use 
in the periconceptional period increased from 15 percent in 1988 to 40 percent in 
2002, which is a slower increase than that seen in Norway (Table 5). 
Table 5. Folic acid supplement use according to month of pregnancy and year 
of birth, MoBa, 2000-2006 
Year 
of birth 
No. of 
subjects 
2 months 
before 
 pregnancy 
1 month 
before 
 pregnancy 
First 
month of 
 pregnancy 
Second 
month of 
 pregnancy 
      
 n % 
2000 1923 7 11 16 31 
2001 3698 9 12 19 35 
2002 8042 10 13 21 36 
2003 11,734 14 19 30 46 
2004 12,518 26 31 48 65 
2005 14,622 30 35 53 70 
2006 13,451 33 39 58 75 
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We found that about 80 percent of the women planned their pregnancy. Hence, our 
findings of low use before pregnancy and high use during pregnancy strongly indicate 
that most women during 2000-2003 were not familiar with the recommended timing 
of folic acid supplement use. Thus, it may still be feasible through effective health 
campaigns to raise the use prior to pregnancy even more. In order to do this, future 
campaigns should focus on the timing, as well as on certain risk groups, which I will 
discuss in the next section. 
We used data from MoBa during 2000-2003, ranging from 2 months before 
pregnancy to approximately the eighth month of pregnancy. Apart from a smaller 
study from the United States (135), ours is the first large-scale study to have 
examined detailed folic acid patterns over the course of pregnancy. Previous studies 
on folic acid awareness and use among fertile women have mainly focused on the 
time period around neural tube closure and not beyond the first 3 months of 
pregnancy. Exploring the use of folic acid supplements beyond the first 3 months is 
also of relevance, because folic acid use during second and third trimester may have a 
beneficial effect on other adverse birth outcomes besides NTDs (11). 
4.2 Predictors of folic acid supplement use 
Periconceptional folic acid supplement use is usually defined as regular use of 400 µg 
folic acid pills from 1 month before pregnancy throughout the 3 first months of 
pregnancy. Because we did not have information on the exact folic acid dosage and 
frequency of use, we extended the definition in paper 1 to include women who used 
any supplements containing folic acid more than once a week throughout the 
periconceptional period (Appendices 3 and 4). 
We found that maternal age, marital status, smoking, maternal and paternal education, 
maternal income, parity, pregnancy planning, and fertility treatment, were all 
independent predictors of periconceptional folic acid use. Consistent with other 
studies (131, 134-137) lower education, living alone, and unplanned pregnancy were 
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the strongest determinants for not taking folic acid in our study. However, those with 
unplanned pregnancies quickly caught up folic acid supplement use during early 
pregnancy, unlike lower educated and single women (Figure 2). 
Figure 2. Monthly prevalence of folic acid supplement use according to 
maternal characteristics, MoBa, 2000-2003 
We also found that high parity was a marked predictor for not taking folic acid. This 
is a particularly important issue, because earlier studies have reported that women 
who have recently undergone a viable pregnancy may become folate deplete in the 
next pregnancy, especially if the inter-pregnancy interval is short (33). Similarly, 
smokers appeared to consume significantly less folic acid supplements than non-
smokers. According to recent studies, smokers tend to have lower blood folate levels 
than non-smokers regardless of dietary folate intake (138-140). Increased 
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periconceptional folate intake in smokers and women with high parity may thus have 
relevance for NTDs and perhaps other pregnancy outcomes as well. 
Surprisingly, women who suffered from epilepsy did not use folic acid supplements 
more than others during the periconceptional period (Figure 2), despite the increased 
need of folate for patients on certain AEDs (95). Although the use of folic acid was 
low for this group during the periconceptional period, it increased substantially from 3 
months of pregnancy and was twice as high as folic acid supplement use for those 
without the disease throughout the eighth month of pregnancy. One explanation for 
the increased use late during pregnancy may be that folic acid information was 
provided by their doctors at their first antenatal visit, which usually occurs within 2-3 
months of pregnancy. 
Our data suggest that recommendations on periconceptional folic acid use are not 
efficient for women with low socioeconomic status (i.e., lower education, low 
income, and single mothers). The use of supplement in lower educated and single 
mothers tended to be extremely low both before and during pregnancy (Figure 2). 
Some authors have speculated whether these groups may be less conscious about 
general health issues (134). Another possibility may be that the health campaigns 
designed to promote folic acid supplement use do not reach these women, perhaps 
because they do not use information channels where information on folic acid can be 
found (e.g., health magazines or health programs on TV). 
4.3 Folate indicators and infant birth size 
Over the years, numerous studies have examined the relation between infant birth size 
and folate status (11). Most of these studies, however, are small and often confined to 
only 1 folate indicator and a few birth size parameters. Furthermore, varying findings 
have been obtained, possibly due to methodological issues, such as the timing of 
folate exposures, lack of control for confounding factors, and a variation in 
population characteristics and nutritional baseline status. 
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In paper 2, we examined the relation between infant birth size and several maternal 
folate indicators, measured during the second trimester. The folate indicators included 
food folate intake, folic acid supplement use, plasma folate, and plasma total 
homocysteine. The birth size parameters were gestational age, infant birth weight, 
head circumference, crown-heel length, and SGA. The paper also assessed the 
association of maternal smoking, which is an established risk factor for small infant 
birth size. The study was based on 2934 women with singleton births in MoBa during 
2002-2003, who had donated a blood sample, returned the baseline questionnaire and 
FFQ around gestational week 18, and who were registered with births in the MBRN. 
About 53 percent of all women had a total dietary folate intake of 400 g or more per 
day. Four women had a total folate intake 100 g/day, and 342 women (11.7 
percent) had a total folate intake 200 g/day. We found that food folate, 
supplemental folic acid, total dietary folate intake, plasma folate, and plasma total 
homocysteine were not statically significantly related to gestational age, infant birth 
weight, head circumference, or crown-heel length. There was a tendency for increased 
SGA risk at lower folate levels, but analyses yielded insignificant associations, 
possibly due to low number of individuals with low folate intake. 
Because most studies differ from each other with respect to population characteristics, 
nutritional baseline status, and the timing and methods used to collect exposures and 
outcomes data, a direct comparison of our study with previous studies is difficult. 
Nevertheless, our results agree with those in a longitudinal study of healthy Japanese 
women that found no association between folate intake during pregnancy and various 
continuous birth size parameters (91). These authors, however, found an inverse 
relation between total homocysteine and infant birth weight in the third trimester, but 
this was not reflected in the analyses of serum or red blood cell folate. 
Our results are in contrast with a recent study from the Netherlands which 
demonstrated that periconceptional folic acid supplementation was associated with 
higher placental and infant birth weight, and decreased risks of low birth weight and 
SGA (<5th percentile) (86). The authors, however, did not include information on 
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several folate indicators, which would have added value to the interpretation of these 
findings. Recently, a study from the United Kingdom reported a higher incidence of 
SGA (<10th percentile) at low folate intake during late pregnancy in an adolescent 
population (140). These authors also showed a greater risk of SGA with lower 
concentrations of serum and red blood cell folate during the third trimester. 
In our study, mean supplemental folic acid intake was higher among women who 
were married or cohabiting, had higher education and lower parity, had lower 
prepregnancy BMI, and did not smoke. However, we found no significant difference 
in mean food folate intake according to these variables, not even according to 
smoking. This is an interesting finding, suggesting that supplement users are not more 
motivated than nonusers to consume more folate from foods. Mean food folate intake 
by supplement groups is shown in Table 6. 
Table 6. Mean intake of food folate among supplement users and nonusers, 
MoBa, 2002-2003 
Food folate Nonusers (0 g/day) Users (1-399 g/day) Users (400 g/day) 
   
g/day  
Mean 264 271 270 
Median 249 258 259 
5th percentile 140 146 152 
95th percentile 429 437 424 
The correlation between plasma folate and food folate intake was relatively low in our 
study (r = 0.07, P <0.001). Nevertheless, this finding is consistent with an 
intervention study from 2000 (141), which showed that increase in foods naturally 
rich in folates (400 g/day) was a relatively ineffective means of increasing red blood 
cell folate status in women compared with equivalent intakes of folic acid-fortified 
food. There may be several reasons for this. First, the folates from foods 
(polyglutamates) are more unstable for cooking and storage and are less bioavailable 
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than synthetic folic acid (monoglutamates) (1). Second, we used non-fasting blood 
samples from MoBa, which may have added pre-analytical variation in plasma folate 
values and thus attenuated correlation with food folate. Third, the MoBa FFQ 
measured the mean food folate intake during the first 4-5 months of pregnancy, which 
may not entirely represent the intake at the time of blood sampling. 
Consistent with previous literature (142, 143), we found that second trimester 
smoking strongly influenced infant birth weight and SGA, suggesting that smoking 
remains a strong risk factor for infant birth size in our population. We also found that 
plasma cotinine was significantly inversely correlated with plasma folate (r = -0.15). 
This correlation was almost unchanged after adjustment for total dietary intake (r = -
0.12), suggesting that smoking alone affects blood folate status. This is also consistent 
with other studies that have examined blood folate status and smoking (138, 139). 
4.4 Vitamin use and placental abruption 
Placental abruption is a complication of pregnancy that causes a premature separation 
of the placenta from the uterus wall (121). This usually occurs in the third trimester, 
often leading to blood loss that can be life-threatening for both mother and child. In 
Norway it affects 4 in 1000 pregnancies, resulting in about 200-240 cases each year. 
Placental abruption is associated with a number of factors, including placental 
abruptions in previous pregnancies (144), maternal smoking (145), and vitamin 
deficiency (65). Although folate and other vitamins measured in blood have been 
associated with placental abruption (62, 64, 65, 74), few studies have addressed 
whether supplemental folic acid or multivitamin use during pregnancy can reduce 
occurrence of this complication. 
In paper 3, we examined whether supplemental folic acid or multivitamin use during 
pregnancy can reduce occurrence of placental abruption. The study was based on 
280,127 singleton deliveries recorded in MBRN in 1999-2004. We found that intake 
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of folic acid and other vitamin supplements before and during pregnancy statistically 
significantly reduced the risk for placental abruption by up to 30 percent. Associations 
between vitamin supplement use and placental abruption were strongest for women 
using both folic acid and multivitamin supplements (OR = 0.68; 95 percent CI: 0.56, 
0.83), followed by multivitamins alone (OR = 0.72; 95 percent CI: 0.57, 0.91) and 
folic acid alone (OR = 0.81; 95 percent CI: 0.68, 0.98), suggesting that other vitamins 
beside folate may have a role in preventing placental abruption. Our data further 
showed that the vitamin - abruption associations were stronger when the placental 
abruption was preterm (<37 weeks gestation), suggesting a different pathogenesis of 
placental abruptions before term in comparison with those at term. 
Our findings are supported by a recent study from Canada in 2009 that found mild to 
severe placental abnormalities due to low folate intake in pregnant mice (146). In that 
study, half of the folate-deficient placenta examined had severe disorders, including 
some degree of separation of the placenta from the maternal decidua, which is similar 
to placental abruption in humans. Our findings also agree with previous results from a 
meta-analysis (65) and other reports (61-64) showing that maternal folate deficiency 
and elevated plasma total homocysteine are associated with increased risk of placental 
abruption. Our results, however, are in contrast with those from a recent report from
Canada, which showed that food fortification with folic acid had no impact on the 
prevalence of placental abruption (147). 
The present paper is the first large study that examines an association of supplemental 
folic acid and multivitamin use with placental abruption, comprising 1070 abruptions 
among 280,127 singleton deliveries. Although the associations are moderate, this 
study suggests that current recommendations to assure adequate intake of folate 
before and during early pregnancy to prevent NTDs may protect against placental 
abruption as well. The absolute risk of placental abruption among users and nonusers 
of folic acid supplements alone were 32 and 44 per 10,000 births (see Table 3 in the 
paper), respectively. Thus, if all pregnant women took folic acid supplements on a 
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regular basis before and/or during pregnancy, 12 in 10,000 abruptions could be 
avoided in Norway each year (corresponds to 60-70 placental abruptions each year). 
4.5 Self-selection and bias 
To evaluate potential bias due to self-selection in MoBa, we studied differences in 
prevalence estimates and association measures between MoBa participants and all 
women giving birth in Norway. Women who agreed to participate in MoBa (43.5 
percent of invited; n = 73,579) were compared with all women giving birth in Norway 
(n = 398,849) using data from the population-based MBRN in 2000-2006. 
Compared to all women giving birth in Norway, participating women were more 
often older, primiparous, non-smokers, and vitamin supplement users. MoBa 
participants also tended to experience less stillbirths and neonatal deaths than those 
who were not included in the study. Despite differences in various exposure and 
outcome variables, we found no statistically significant relative deviation in 8 studied 
exposure-outcome associations if they were based on the MoBa participants instead of 
the total population. For instance, the risk (measured in OR) for infant low birth 
weight (<2500 g) for smokers was 1.77 (95 percent CI: 1.53, 2.05) among MoBa 
participants and 1.85 (95 percent CI: 1.76, 1.94) among all women giving birth in 
Norway, relative to non-smokers. 
Many authors have discussed the consequences of self-selection and low participation 
rate in prospective studies (148-150). Consistent with our findings, bias is often found 
in the prevalence of exposures and outcomes, but to a less extent in effect estimates of 
exposure-outcome associations. In general, this is not surprising as data on the 
exposures in prospective studies are usually collected before the outcome under study. 
However, both the risk factor and the outcome may sometimes be strongly associated 
with some underlying factor that is also associated with participation. For that reason, 
researchers should always consider the possibility of selection bias related to their 
exposures and outcomes. 
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A selective sample which is not representative of the target population may have 
advantages, because it may provide better control for confounding factors that vary in 
the general population (151). For instance, in studies of causality, one usually wants 
to select study groups that are homogenous and highly comparable with respect to 
certain characteristics, rather than to make the study sample representative (151). A 
weakness of a selective sample, however, is that the number of exposed may be 
lower/higher than that found in the target population, resulting in a lower statistical 
power of effect estimates. In a case-cohort study based on MoBa, one therefore 
always should calculate the sample size needed based on the study's exposure and 
outcome prevalence in the full cohort. 
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5. Methodological considerations 
We performed observational research based on existing data from MoBa and MBRN. 
When interpreting results from observational data one should recognize both the 
methodological strengths and limitations of the data. 
5.1 Study design 
All papers in this thesis comprised sufficient statistical power to detect moderate to 
strong estimates of associations between exposures and outcomes. Although 
inferences of some sub-group analyses were problematic due to small numbers, 
precision of the estimates was generally not a problem when the inferences were 
made from the overall results. 
The major strength of MoBa is the prospective design in which folate indicators are 
measured before the outcome under study. Well-designed prospective designs are 
generally robust for systematic errors and are considered to have high internal 
validity. However, as described in the previous chapter, the possibility of systematic 
errors, such as selection bias, should still always be discussed in light of the exposure 
and outcome analyzed, especially if the response rate is low. Furthermore, the study 
participants of MoBa are not representative of the total Norwegian pregnant 
population. This could influence the external validity of study results. 
The major strength of MBRN is the compulsory registration of all live births and 
stillbirths in Norway. The full coverage of births makes it possible to produce 
association measures with high precision and high external validity. Unless data are 
not extensively missing in the registry, selection bias is not considered a problem. 
Nevertheless, some exposure data in MBRN, including prenatal vitamin supplement 
use, are collected during hospitalization around the time of birth. This retrospective 
design could be problematic by introducing information bias in studies. 
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Timing of exposures 
Timing of folate exposures may be important when investigating pregnancy outcomes 
(152). If information on exposures is collected at an irrelevant time point in 
pregnancy, no association may be found. For instance, there will be no causal 
association between third-trimester folic acid supplement use and NTDs, as the neural 
tube closes already within the first month of pregnancy. 
During pregnancy, there is an increase in the red cell mass, enlargement of uterus, and 
a growth of the placenta and infant (153). Thus, adequate folate intake with respect to 
normal cell growth and fetal development is probably equally relevant at any stage of 
pregnancy. In paper 2, plasma folate was measured around 18 weeks of gestation and 
dietary folate intake during the first 4-5 months of pregnancy. However, there were no 
significant associations of these variables with gestational age, infant birth weight, 
head-circumference, crown-heel length or SGA, which are applied, but simple, 
indicators of fetal growth and development (154). 
A low folate intake prior to pregnancy has been associated with a number of placental 
abnormalities in mice, including placental abruption (146). Thus, maternal folate 
status may be particularly important at conception and during the trophoblast invasion 
of the human decidua. In paper 3, women were classified according to folic acid 
and/or multivitamin use before and during pregnancy, during pregnancy only, and 
before pregnancy only. The magnitude of the associations was similar for all time-
windows. However, time-windows largely overlapped and, therefore, no firm 
conclusions could be drawn regarding timing and supplement use in this study. 
Patterns of exposures 
Also patterns of folate exposures during pregnancy may be important when 
investigating pregnancy outcomes (152). Although intake of food folate appears 
relatively stable over the course of pregnancy (90), some studies, including ours 
(paper 1) have shown significant changes in supplement use during pregnancy, with 
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more use earlier, and less use during the third trimester (135). Likewise, several 
studies have shown that blood folate concentrations decline significantly during 
gestation, partly due to hemodilution and increased folate excretion (30-32). Thus, 
studying different time-windows of supplement use or blood folate status in relation 
to birth outcomes may produce different results, which further confirm the need for a 
longitudinal design of folate exposures and pregnancy outcomes. 
5.2 Internal validity 
Internal validity refers to the extent to which scientific inference can be drawn for the 
population under study (151). In order to obtain high internal validity in observational 
research, case and comparison groups should be selected and compared in a manner 
that reduces systematic errors. The 3 main sources of systematic errors that may 
influence internal validity are selection bias, information bias, and confounding (151). 
Selection bias 
Selection bias is a systematic error that results from the methods used to include study 
participants and from factors that influence study participation (151). Selection bias 
usually refers to a situation when risk estimates of exposure-outcome associations of 
the responding population differ from those eligible for the study, including the non-
participants. 
We have shown in paper 4 that self-selection in MoBa at recruitment does not 
necessarily lead to biased association measures, even though exposures are 
underrepresented or overrepresented in the cohort study. Furthermore, in papers 1 and 
2, subjects were selected according to short-term follow-up criteria (Table 2). The 
total loss of subjects at follow-up was only 11 and 16 percent, respectively, and may 
therefore not have influenced exposure-outcome associations in these papers. In paper 
1, we also provided prevalence estimates of folic acid supplement use from 2 months 
before pregnancy through the eighth month of pregnancy. Because women who used 
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folic acid and multivitamin supplement use were markedly overrepresented in MoBa 
(paper 4; relative deviation 31-43 percent), these prevalence estimates cannot directly 
be used to describe the total pregnant population in Norway. 
In paper 3, we used data from MBRN to examine associations of folic acid and 
multivitamin use with the risk of placental abruption. In this study, we excluded 
subjects that had no information on vitamin supplement use (n = 55,972). Notably, the 
information on vitamin use was missing for 17 percent of non-abruptions (55,569/ 
334,626) and 27 percent of placental abruptions (403/1473). To examine potential 
selection bias due to missing data, we compared women with and without data on 
vitamin use for women with or without placental abruption, according to maternal 
characteristics (see Table 4 in paper 3). This comparison showed essentially no 
differences in characteristics between the groups, suggesting no selection bias. 
Because placental abruption is a serious condition that needs immediate medical 
attention, the registration of vitamin supplement use may not have been completed in 
many placental abruption cases. This may explain the larger percent of missing 
vitamin data among women with placental abruption in MBRN. 
Information bias 
Information bias is a systematic error that results from incorrect measurement or 
classification of the exposure or outcome variable under study (151). Information bias 
is usually grouped into 2 types: differential and non-differential misclassification. 
Differential misclassification 
Misclassification of exposure or outcome variables that depend on the value of the 
other is referred to as differential misclassification and can either overestimate or 
underestimate the risk measure. An example of this is recall bias, a situation in which 
for instance dietary intake of certain food items is better recalled by women who had 
a baby with birth defect than those who did not. In the following, I discuss differential 
misclassification with regard to papers 2 and 3. 
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In paper 2, all folate exposures were collected from self-administered questionnaires 
and from blood samples during second trimester (from MoBa), whereas information 
on birth outcomes, such as infant birth weight and SGA, were based on hospital 
records at the time of birth (from MBRN). By using independent data sources for 
exposures and outcomes in a prospective design like this, we have no reason to 
suspect that any misclassification of the various folate indicators and birth outcomes 
could have been differential. 
In paper 3, information on prenatal vitamin supplement use for women with and 
without placental abruption was collected retrospectively during hospitalization at the 
time of birth and not during the earlier stages of pregnancy. Although such study 
design may be susceptible for recall bias in general, we do not suspect that the use of 
vitamin supplements has been recalled differently among mothers with and without 
placental abruptions. Vitamin supplements are taken voluntarily, often on a regular 
basis, to obtain increased health benefits, like prevention of NTDs, and are thus not 
easily forgotten. 
Non-differential misclassification 
Misclassification of exposure or outcome variables that do not depend on the value of 
the other is referred to as non-differential misclassification. If the exposure and 
outcome variables are dichotomous, non-differential misclassification leads to 
attenuated risk estimates. With more than 2 levels, exaggerated risk estimates may 
occur (151). In the following, I discuss possibilities of non-differential 
misclassification for the papers 1 through 3. 
Supplement use: In the MoBa baseline and follow-up questionnaires (Appendix 3 
and 4), women were asked to report in detail which vitamins/minerals that were taken 
according to the label on their supplement containers. This is a rather time-consuming 
and complex procedure, which may have caused underreporting of the use of 
supplements. In MBRN (Appendix 7), information was collected during 
hospitalization by the attending health personnel. Information on supplement use may 
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have been underreported or registered incorrectly by the hospitals. Also women 
themselves may have underreported supplement use or provided incorrect 
information. 
Dietary folate intake: In the MoBa FFQ (Appendix 5), which assessed dietary habits 
during the first 4-5 months of pregnancy, food intake were reported by stating how 
often women consumed numerous food items from never to several times monthly, 
weekly, or daily. Similarly, the frequency of vitamin supplement use ranged from 
never to 7 times per week, and the quantity was reported by the number of tablets, 
capsules, or spoons. The validity of estimated dietary folate intake, thus, relies on the 
participants' ability to recall exactly what they have consumed during the first part of 
pregnancy. 
Folate degradation: EDTA plasma samples were transported from the hospitals to the 
BioBank of MoBa by ordinary mail, usually 1-2 days after blood sampling. Under 
such conditions, folate concentration in EDTA plasma is likely to decrease, especially 
in the absence of a stabilizer like ascorbic acid (155, 156). However, with the strong 
inverse correlation between plasma folate and total homocysteine (Spearman r = -
0.48), which is stable at room temperature, such degradation likely occurs at a 
constant rate over the whole distribution of plasma folate. This suggests that 
remaining biologically active folate still reflects overall folate status and that the 
relative difference in folate concentration between women may have been upheld. 
Infant birth size: Infant birth weight, head circumference, and crown-heel length 
were measured by the attending health personnel immediately after birth, whereas 
gestational age was based on second trimester ultrasound measurements or the date of 
the last menstrual period. Any biases in these measures are likely to be random and 
not systematic. Infant SGA was calculated based on weights from a national reference 
population (120). Since MoBa participants delivered infants with higher mean birth 
weight compared with all women giving birth in Norway, this resulted in a lower 
percentage of SGA in MoBa. 
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Placental abruption: Placental abruption in MBRN has not been validated against 
hospital charts. Thus, whether the report of placental abruption was subject to some
underreporting or overreporting in MBRN is not known. Nevertheless, the prevalence 
of placental abruption among singleton pregnancies in MBRN was 0.38 percent, 
which is similar to what have been reported in other North-European countries. 
Placental abruption was reported in 0.41-0.51 percent among singleton births in 
Sweden (145, 157), and in 0.42 percent among all births in Finland (158). 
Confounding 
Confounding is a situation in which a third factor explains all or part of the observed 
association between the exposure and the outcome under study (151). In order to be a 
confounding factor (confounder), the factor must be associated with the exposure in 
the source population, as well as being a risk factor for the outcome, and it must not 
be an intermediate step in the causal pathway between the exposure and outcome 
(151). To reduce the effect of a possible confounder, the observed association should 
be corrected for its effect. 
A problem in epidemiologic research is over-adjustment bias and unnecessary 
adjustment (159). Over-adjustment bias can be defined as control for an intermediate 
variable on a causal path from exposure to outcome. Unnecessary adjustment can be 
defined as control for a variable that does not affect the causal relation between 
exposure and outcome but may affect its precision. Opposed to unnecessary 
adjustment, lack of important data can lead to unknown or unmeasured confounding. 
Several approaches may be used when evaluating confounding in observational 
research. In papers 1 through 4, potential confounding factors were chosen a priori
and examined according to their influence on the risk estimates. 
Paper 1: Potential confounding factors were evaluated in multiple regression 
analyses. Variables that had little or no influence on study results were not included in 
the final statistical models. The remaining factors for adjustment were maternal age, 
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marital status, maternal education, parity, and year of delivery. The RRs of predictors 
for supplement use were attenuated after adjustment. 
Paper 2: Potential confounding factors were evaluated in unadjusted logistic 
regression models. Variables that were significantly associated with both folic acid 
supplement use and SGA were included in the final statistical models: maternal age, 
marital status, maternal education, parity, prepregnancy BMI, and smoking. For 
dietary analyses, additional adjustment was made for folic acid supplement use and 
total energy intake (160). Furthermore, because dietary habits and plasma vitamins 
change during pregnancy, the analyses were adjusted for gestational age at blood 
sampling and at the time of returning the FFQ. Overall, adjustment had little impact 
on the observed results. 
Paper 3: Potential confounding factors were maternal age, marital status, parity, 
smoking, pregestational diabetes, and chronic hypertension. All variables were 
associated with vitamin supplement use and placental abruption in both unadjusted 
and adjusted logistic regression analyses. We had no information on prepregnancy 
BMI, educational level, and total energy intake, which could have resulted in 
unmeasured confounding. However, adjustment for existing variables had little 
influence on the risk estimates, suggesting that other variables have to be strongly 
associated with both outcome and exposure in order to be important confounders. In 
Scandinavia, educational level or prepregnancy BMI appear not to be strongly 
associated with placental abruption (157, 161, 162). 
Paper 4: It was important to demonstrate that ORs for 8 studied exposure-outcome 
associations were similar for participants and for the total population before and after 
adjustment for potential confounders. We selected a number of potential confounders 
that we knew had some influence on the associations: maternal age, marital status, 
parity and smoking at the end of pregnancy. For simplicity, all adjustment variables 
were included in each of the exposure-outcome analyses, although they were not 
evaluated for their actual confounding ability. The adjustment procedures had some 
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impact on the association estimates, but they did not alter systematically the 
deviations in ORs between the 2 populations. 
5.3 External validity 
External validity (or generalizability) refers to the ability to generalize results and 
conclusions from the population under study to people outside that population (151). 
To achieve high external validity of prevalence estimates, we need our study 
population to be representative of the larger population. However, representativeness 
is generally not a prerequisite when the scientific goal is to report generalizable effect 
estimates. For instance, in paper 4, we found no statistically significant relative 
deviation in ORs for eight studied exposure-outcome associations if they were based 
on the MoBa participants instead of the total population of Norwegian pregnant 
women, even though several exposures and outcomes were overrepresented or 
underrepresented in MoBa. 
Paper 1: We included women who had completed a baseline questionnaire and a 
follow-up questionnaire at week 30. Thus, the patterns and predictors of folic acid 
supplement use may only be generalized to those who delivered after 30 weeks of 
gestation. Furthermore, since the percentage of vitamin users is markedly 
overrepresented in MoBa (as shown in paper 4) the prevalence estimates in paper 1 
cannot be generalized to the total Norwegian pregnant population. The internal 
exposure-outcome associations, on the other hand, were shown in paper 4 to be 
generalizable to Norwegian pregnant women in general, suggesting that the predictors 
in paper 1 also are generalizable to pregnant women outside MoBa. 
Paper 2: We only included women with singleton pregnancies. Furthermore, using 
limits from Norwegian guidelines for nutritional intake (163), we discovered that only 
4 women had a daily folate intake below the lower limit (100 µg/day), and only 342 
women (11.7 percent) had a daily folate intake below the limit of estimated average 
requirements (200 g/day). Although folate-deficient women are present in our study 
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sample, the prevalence of folate-deficient women may be too small in order to 
generalize our null-findings in this paper to the total pregnant population in Norway. 
Paper 3: We used data from the population-based MBRN. The study may therefore 
be generalizable to all women giving birth in Norway, except for those who had 
multiple pregnancies. Multiple pregnancies were excluded for 12,944 women (3.7 
percent), because they might involve complex confounding mechanisms that differ 
from those in singleton gestations (164). 
5.4 Effect modification 
Effect modification is a situation in which the effect measure of an exposure on the 
outcome varies according to the levels of a third variable (151). While confounding is 
considered a confusion of effects, effect modification is a property of the effect under 
study. In this thesis, effect modification was evaluated by stratification and the 
inclusion of interaction terms in multiple logistic regression models. 
Paper 2: We examined whether the effects of several folate indicators on SGA were 
different for smokers and non-smokers, but found no statistical evidence of effect 
modification, possibly due to low numbers of smokers and SGA cases (i.e., 49 
women). The rationale for testing smoking as an effect modifier is that smokers tend 
to have less blood folate than non-smokers, independent of folate intake (140). Since 
smoking is associated with SGA, we hypothesized that folate could be more 
beneficial for smokers than non-smokers. 
Paper 3: We examined effect modification of the association between vitamin use and 
placental abruption by smoking and preeclampsia, but differences in ORs between 
strata of these variables were statistically insignificant. Evaluating preeclampsia as an 
effect-modifier was initially done to rule out that the effect of folic acid supplement 
use on placental abruption was mediated through preeclampsia. Preeclampsia is a risk 
factor for placental abruption (121) and have been associated with vitamin use (165). 
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6. Conclusions and implications 
In this thesis, we have used existing data from MoBa and MBRN to study several 
folate indicators, including folic acid supplement use, and their relation to birth 
outcomes in Norwegian pregnant women. The following conclusions can be drawn 
for each question: 
1. To which extent do Norwegian pregnant women follow the recommendations 
regarding periconceptional folic acid supplement use? 
We found that 72 percent of the participants in 2000-2003 had used folic acid-
containing supplements at some time before or during pregnancy. Of these, more 
than 70 percent had started use after becoming pregnant, the majority during the 
first and second month of pregnancy. Only 10 percent of participants had taken 
folic acid supplements regularly from 1 month before pregnancy throughout the 
first 3 months of pregnancy. The low use before conception indicates that women 
are unaware of the recommended timing of use. 
2. Which maternal factors predict periconceptional folic acid supplement use 
among Norwegian pregnant women? 
Maternal age, marital status, smoking, maternal and paternal education, maternal 
income, parity, pregnancy planning, and fertility treatment, were all independent 
predictors of regular folic acid supplement use during the periconceptional period. 
Low education, living alone, and unplanned pregnancy were the strongest 
determinants for not taking folic acid. Notably, women who suffered from 
epilepsy did not use folic acid more often than others during the periconceptional 
period, despite the special recommendation for women on AED. 
3. Is infant birth size associated with second trimester folate status in 
Norwegian pregnant women? 
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Second trimester folate indicators in terms of food folate, supplemental folic acid, 
total dietary folate intake, plasma folate, and plasma total homocysteine did not 
statistically influence the size of the infant, measured as gestational age, infant 
birth weight, head circumference, crown-heel length, or SGA. The absence of 
statistically significant associations might be explained by an adequate intake of 
folate from diet and supplements in most women in our study population. 
4. Is periconceptional folic acid and multivitamin supplement use associated 
with placental abruption in Norway? 
Use of folic acid and other vitamin supplements before and during pregnancy 
reduced the risk for placental abruption by up to 30 percent. The association 
between vitamin supplement use and placental abruption was strongest for women 
using both folic acid and multivitamin supplements. 
5. Are prevalence estimates of exposure and outcome variables in MoBa 
different from those of all women giving birth in Norway? 
Significant relative deviations in prevalence estimates were found in most of the 
23 exposure and outcome variables studied, including vitamin use and smoking. 
Ten of the variables deviated with more than 15 percent. 
6. Are exposure-outcome associations in MoBa different from those of all 
women giving birth in Norway? 
We found no statistically significant relative deviation in OR estimates for 8 
studied exposure-outcome associations if they were based on the MoBa 
participants instead of the total population. 
In summary, many women use supplements containing folic acid in connection with 
pregnancy, but start too late with respect to NTD prevention. Still, increased intake of 
folate during pregnancy may have benefits. Our finding of a risk reduction in 
65
placental abruption with folic acid supplementation supports findings from the 1960s 
and 1970s. If proven in trials, current recommendations to assure adequate intake of 
folate before and during early pregnancy to prevent NTDs may be extended to 
placental abruption as well. 
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7. Perspectives 
7.1 Future studies 
A general limitation of paper 2 is that information on folate exposures was collected 
only once during pregnancy. Particularly, we did not have information on plasma 
folate and folate consumption during late pregnancy, when the growth of the infant is 
greatest (166). Because plasma folate and growth rate may change during pregnancy, 
the cross-sectional nature of our study can lead to some exposure misclassification 
(152), which again may lead to some underestimation of possible effects of these 
folate indicators. To avoid this problem, future studies of infant birth size should 
include longitudinal data on vitamin exposures. 
Studies have reported that women who have recently undergone a viable pregnancy 
may become folate deplete in the next pregnancy, especially if the inter-pregnancy 
interval is short (33). We further showed that high parity was a marked predictor for 
not taking folic acid. Hence, both inter-pregnancy interval and parity seem to be 
important covariates, and should always be included in future studies of pregnancy 
outcomes and folate values. Furthermore, because the utilization of folate depends on 
other B-vitamins in the folate metabolism, future studies of inter-pregnancy interval 
and nutritional status should also include these and related metabolites to obtain a 
more complete picture of one-carbon metabolism in pregnancy. 
MoBa is a long-term follow-up study that includes more than 100,000 pregnancies 
between 1999 and 2008. The participants received 3 self-administered questionnaires 
by mail during the pregnancy, and another 4 during the infant’s early childhood. In 
addition, the women were asked to give 1 blood sample during pregnancy and 1 blood 
sample immediately after delivery. Further questionnaires are planned during 
childhood and adolescence. Because not all women are able or willing to follow up on 
each event, some selection bias due to loss to follow-up can be introduced. A study of 
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loss to follow-up is thus needed, especially after delivery during which response rate 
for questionnaires are lower than that before pregnancy (113). 
7.2 Recent developments 
Recent studies of non-pregnant individuals, including randomized trials, indicate that 
high folate doses may have potentially adverse effects by accelerating the growth of 
premalignant and malignant lesions (106, 107). Furthermore, it is suggested that 
unmetabolized folic acid in blood is associated with reduced natural killer cell 
cytotoxicity, a component of the nonspecific immune response (167). 
Recent scientific developments have raised concerns regarding folic acid supplement 
use also in pregnant women. A Norwegian study from 2009 provided some evidence 
that supplemental folic acid during pregnancy may increase the risk of certain infant 
respiratory diseases in early childhood (168). This finding was supported by a study 
from Australia (169), which showed that folic acid taken in supplement form in late 
pregnancy was associated with an increased risk of childhood asthma at 3.5 years (RR 
= 1.26; 95 percent CI: 1.08, 1.43) and with persistent asthma (RR = 1.32; 95 percent 
CI: 1.03, 1.69). 
Although randomized controlled trials have proven the beneficial effect of folate 
supplementation on the prevention of NTDs we do not have the full picture of 
potential adverse effects of folic acid supplement use in pregnant women. Therefore, 
it is also important to monitor possible adverse effects of prenatal folic acid 
supplementation, especially in countries were also mandatory and voluntary food 
fortification with folic acid are practiced. 
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IAppendix
Notification form for MBRN (1998 -) 
Institusjonsnr:
Mors
fødselsnr:
Mors fulle navn og adresse
Pikenavn (etternavn):
Fars fulle navnFars
fødselsdato
Siste menstr.
1. blødn.dag
Ultralyd  utført?
Nei
Ja
UL
termin:
Mors
sivilstatus
Slektskap mellom
barnets foreldre?
Nei
Ja
Hvis ja,
hvorledes:
Gift
Samboer
Ugift/enslig
Skilt/separert/enke
Annet
Hjemme, planlagt
Hjemme, ikke planlagt
Under transport
Annet sted
Sikker
Usikker
Mors tidligere
svangerskap/fødte
Levende-
fødte
Dødfødte (24.
uke og over)
Spontanabort/Død-
fødte (12.–23. uke)
Spontanaborter
(under 12. uke)
Fødsel utenfor institusjon:
Annen prenatal
diagnostikk?
Nei
Ja, angi type:
Patologiske funn ved
prenatal diagnostikk? Ja, hvis bekreftet – spesifiser
Nei
Spesielle forhold
før svangerskapet:
Intet spesielt
Astma
Allergi
Tidligere sectio
Kronisk nyresykdom
Res. urinveisinfeksjon
Kronisk hypertensjon
Hjertesykom
Epilepsi
Diabetes type 1
Reumatoid artritt
Annet, spesifiser i «B»
Intet spesielt
Regelmessig kosttilskudd:
Nei
Spesifikasjon av forhold før eller under svangerskapet:
Før sv.sk. I sv.sk.
Multivitaminer
Folat/Folsyre
Legemidler i svangerskapet:
Nei
Ja – spesifiser i «B»
Spesielle 
forhold under
svangerskapet:
Blødning < 13 uke
Blødning 13–28 uke
Blødning > 28 uke
Glukosuri
Svangerskapsdiabetes
Hypertensjon alene
Preeklampsi lett
Preeklampsi alvorlig
HELLP syndrom
Preeklampsi før 34. uke
Eklampsi
Hb < 9.0 g/dl
Hb > 13.5 g/dl
Trombose, beh.
Forutsetter mors samtykke
– se rettledning på baksiden
Skriftlig orientering gitt til mor
Samtykker ikke for røykeoppl.
Røykte mor ved
sv.sk. begynnelse?
Nei
Av og til
Nei
Av og til
- ved sv.sk.
avslutning?
Daglig
Daglig
Ant. sig. dagl.:
Ant. sig. dagl.:
Mors
yrke
Samtykker ikke for yrkesoppl.
Ikke yrkesaktiv
Yrkesaktiv heltid
 Yrkesaktiv deltid
Mors yrke
Bransje:
Leie/presentasjon:
Normal
bakhode
Inngrep/tiltak
Ingen
Anestesi/analgesi:
Sete
Tverrleie
Avvikende hodefødsel
Annet, spesifiser i «C»
Fødselstart:
Spontan
Indusert
Sectio
Ev. induksjons-
metode:
Prostaglandin
Oxytocin
Amniotomi
Annet, spesifiser i «C»
Indikasjon for
inngrep og/eller 
induksjon
Komplikasjoner som beskrevet nedenfor
Fostermisdannelser
Overtid
Annet, spesifiser i «C»
Spesifikasjon av forhold ved fødselen/andre komplikasjoner
Ingen
Ingen
Placenta:
Normal
Fremhj. ved setefødsel:Utskj. tang, hodeleie Sectio:
Annen tang, hodeleie
Vakuumekstraktor
Episitomi
Vanlig fremhjelp
Uttrekning
Tang på etterk. hode
Utført som elektiv sectio
Utført som akutt sectio
Nei JaVar sectio planlagt før fødsel?
Annet:
Annet:
Komplikasjoner Vannavg. 12–24 timer
Vannavg. > 24 timer 
Mekaniske misforhold
Vanskelig skulderforløsning
Placenta previa
Abruptio placentae
Perinealruptur (grad 1-2)
Blødn.> 1500 ml, transf. Truende intrauterin asfyksi
Risvekkelse, stimulert
Langsom fremgang
Uterus atoniSphincterruptur (gr. 3-4)
Blødning 500–1500 ml
Eklampsi under fødsel
Navlesnorfremfall
Lystgass
Petidin
Epidural
Spinal
Pudendal
Infiltrasjon
Paracervical blokk
Narkose
Navlesnor Fostervann Komplikasjoner hos mor etter fødsel
Normal Normal Intet spesielt
Hinnerester
Ufullstendig
Infarkter
Koagler
Utskrapning
Manuell uthenting Velamentøst feste
Marginalt feste
Karanomalier
Omslyng rundt hals
Annet omslyng
Ekte knute Polyhydramnion
Oligohydramnion
Misfarget
Stinkende, infisert
Blodtilblandet
Feber > 38.5˚
Trombose
Eklampsi post partum
Mor overflyttet
Mor intensivbeh.
Sepsis
Annet, spesifiser
Placenta-
vekt
Navlesnor-
lengde:
Fødselsdato Klokken Pluralitet Barnets
vekt:
Total
lengde:
Eventuelt
sete–issemål:
1 min
5 min
Apgar score:
Hode-
omkrets:
Av
totaltNr.
Kjønn
Enkeltfødsel
Flerfødsel
For flerfødsel: Gutt
Pike
Ved tvil spesifiser i «D»
Barnet var:
Overfl. barneavd.
Neonatale diagn.:
(Fylles ut av
lege/pediater)
Tegn til
medfødte 
misdannelser:
Levendefødt
Nei
Nei
Ja
Ja
Intet spesielt
Dødfødt/sp.abort
For dødfødte: Død før fødsel
Død under fødselen
Ukjent dødstidspunkt
For dødfødte, oppgi også
Død før innkomst
Død etter innkomst
Levendefødt, død innen 24 timer Død senere (dato): Klokken
Livet
varte: Timer Min.
Dato:
Overfl. til Indikasjon for
overflytting:
Respirasjonsproblem
Prematur
Medfødte misd.
Perinatale infeksjoner
Annet, spesifiser
Hypoglyk. (< 2 mmol/l)
Medf. anemi (Hb < 13.5 g/dl)
Hofteleddsdyspl. beh. m/pute
Transit. tachypnoe
Resp. distress syndr.
Aspirasjonssyndrom
Intrakraniell blødning
Cerebral irritasjon
Cerebral depresjon
Abstinens
Neonatale kramper
Konjunktivitt beh.
Navle./hudinf. beh.
Perinat. inf. bakterielle
Perinat. inf. andre
Fract. claviculae
Annen fraktur
Facialisparese
Plexusskade
Systemisk antibiotika
Respiratorbeh.
CPAP beh.
Lysbehandlet
Utskifting
AB0 uforlik.
RH immunisering
Fysiologisk
Annen årsak
Behandlingskoder: Icterus behandlet:
D 
– 
O
m
 b
ar
ne
t
C 
– 
O
m
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ds
el
en
B 
– 
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Spesifikasjon av skader, neonatale diagnoser og medfødte misdannelser – utfylles av lege
Jordmor v/fødsel:
Jordmor v/utskrivning:
Lege:
Mor:
Barn:
Melding om avsluttet svangerskap etter 12. uke – Fødsel, dødfødsel, spontanabort
Diabetes type 2
B
Røyking og yrke
C
For dødfødte: Usikkert kjønn
Oppgi dødsårsak i «D»
D
Protokollnr.: /
Se utfyllingsinstruks for blanketten på baksiden
Institusjonsnavn
Infeksjon, spes. i «B»
Annet, spesifiser i «B»
Årsak:
Mors
bokommune
Kryss av hvis skjema
er oppfølgingsskjema
Utskrivningsdato
Lege
barsel/barneavd:

IIAppendix
Data collection in MoBa 
Time schedule of all MoBa questionnaires and blood samples by January 
2009. 
  Questionnaire (Q)a  Blood sample (B)b 
Time   Mother Infant Father  Mother Infant Father 
         
Pregnancy week 18  Q1b  Q1  B1  B1 
Pregnancy week 18/22c  Q2b       
Pregnancy week 30  Q3       
Delivery       B2 B1d  
Child age 6 months  Q4     
Child age 18 months  Q5     
Child age 36 years  Q6     
Child age 7 years  Q7     
a
 Q, questionnaire; B, blood sample. Numbers followed by Q or B indicate the order of 
questionnaires and blood samples. Bold face indicates data sources used in this thesis. 
b
 Q1 is the baseline questionnaire and Q2 is the FFQ. 
c
 Q2 was sent out at gestational week 22 from April 2004. 
d
 B1 from the child at delivery was taken from the umbilical cord. 
 
 
Webpage link for pdf-versions of the entire questionnaires: 
www.fhi.no/artikler/?id=51491 

IIIAppendix
Supplement use at baseline in MoBa 
Page 7 of the baseline questionnaire returned around gestational week 18. 
The complete questionnaire can be found at: www.fhi.no/artikler/?id=51491. 
7
When did you take the supplements?
26-9 8-5 4-0 0-4 5-8 9-12 13+
weeks weeks      weeks weeks weeks weeks weeks
1 Folate/folic acid  . . . . . . . . . . . . . .
2 Vitamin B1 (Thiamine)  . . . . . . . . . .
3 Vitamin B2 (Riboflavin) . . . . . . . . . .
4 Vitamin B6 (Pyridoxine)  . . . . . . . . .
5 Vitamin B12  . . . . . . . . . . . . . . . . . .
6 Niacin . . . . . . . . . . . . . . . . . . . . . . .
7 Pantothenic acid  . . . . . . . . . . . . . .
8 Biotin  . . . . . . . . . . . . . . . . . . . . . . .
9 Vitamin C  . . . . . . . . . . . . . . . . . . . .
10 Vitamin A  . . . . . . . . . . . . . . . . . . . .
11 Vitamin D  . . . . . . . . . . . . . . . . . . . .
12 Vitamin E  . . . . . . . . . . . . . . . . . . . .
13 Iron . . . . . . . . . . . . . . . . . . . . . . . . .
14 Calcium  . . . . . . . . . . . . . . . . . . . . .
15 Iodine . . . . . . . . . . . . . . . . . . . . . . .
16 Zinc  . . . . . . . . . . . . . . . . . . . . . . . .
17 Selenium  . . . . . . . . . . . . . . . . . . . .
18 Copper . . . . . . . . . . . . . . . . . . . . . .
19 Chromium  . . . . . . . . . . . . . . . . . . .
20 Magnesium  . . . . . . . . . . . . . . . . . .
21 Cod liver oil  . . . . . . . . . . . . . . . . . .
22 Omega-3 fatty acid  . . . . . . . . . . . .
44. Have you used other medication not previously mentioned?  If yes, which and when did you take them? 
Use of medication during pregnancy weeks
0-4        5-8        9-12 13+Name of medication 
(e.g. Valium, Rohypnol, Paracetamol)
_________________________________________________________
_________________________________________________________
_________________________________________________________
_________________________________________________________
_________________________________________________________
Last 6 months
before pregnancy
Number
of days used
Other medicines
46. If yes, fill in the table below for the vitamins and minerals found in the contents list on the vitamin package/bottle. (For instance, if you have
taken cod liver oil for the last six months before becoming pregnant, enter a cross for each period under “When” (i.e. 7 crosses) and enter a cross in “Daily” under “How often”).
Last 6 months before pregnancy         During pregnancy
40. Do you have a congenital malformation/birth defect?
No
Yes
41. If yes, which? ____________________________________
42. Do your gums bleed when you brush your teeth at present?
No, rarely or never
Yes, sometimes 
Yes, often
Yes, almost always
43. If you had diabetes before you became pregnant, what was
your last long-term blood sugar level (HbA1c) before you
became pregnant?
Less than 7.5
7.5 - 12
More than 12
Don’t Know
Vitamins, minerals and dietary supplements
45. Do you take vitamins, minerals or other dietary supplements? 
No (proceed to question 49) 
Yes
In this period how often 
did you take this?
Daily 4-6 times 1-3 times
a week a week

IVAppendix
Supplement use at follow-up in MoBa 
Page 7 of the follow-up questionnaire returned around gestational week 30. 
The complete questionnaire can be found at: www.fhi.no/artikler/?id=51491. 
Week of pregnancy supplement taken? How often did you take this supplement?
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
7
54. Have you taken other medication after the 13th week of pregnancy not previously mentioned, for example, sleeping tablets or sedatives? Give
the name, when and how many days altogether the medication was taken for. (This applies to all types of medicines including alternative and herbal
remedies, both regular and occasional use. Do not include vitamins and nutritional supplements as these are discussed elsewhere.)
Name of medication Use of medication in week of pregnancy No. of days
(e.g. Valium, Rohypnol, Paracetamol) 13–16 17–20 21–24 25–28 29+ taken
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
55. During this pregnancy have you been involved in an accident or been 56. If yes, in which week of pregnancy?
injured (e.g. traffic accident, fall, hit in the stomach)?
■  No
■  Yes
57. Have you taken vitamins, minerals or other nutritional supplements after the 13th week of pregnancy?
■  No (go to question 61)
■  Yes
If you take supplements, please find the package/bottle.
58. Fill in the table below for the vitamins and minerals found on the vitamin package/bottle. Fill in when and
approximately how often you have taken them.
Vitamins, minerals and dietary supplements
1  Folate/folic acid  . . . . . . . . . . . . . . . . .
2  Vitamin B1 (Thiamine)  . . . . . . . . . . .
3  Vitamin B2 (Riboflavin)  . . . . . . . . . . .
4  Vitamin B6 (Pyridoxine)  . . . . . . . . . .
5  Vitamin B12   . . . . . . . . . . . . . . . . . . .
6  Niacin  . . . . . . . . . . . . . . . . . . . . . . . .
7 Pantothenic acid  . . . . . . . . . . . . . . . .
8  Biotin  . . . . . . . . . . . . . . . . . . . . . . . .
9  Vitamin C  . . . . . . . . . . . . . . . . . . . . .
10  Vitamin A  . . . . . . . . . . . . . . . . . . . . .
11  Vitamin D  . . . . . . . . . . . . . . . . . . . . .
12  Vitamin E  . . . . . . . . . . . . . . . . . . . . .
13  Iron  . . . . . . . . . . . . . . . . . . . . . . . . . .
14  Calcium  . . . . . . . . . . . . . . . . . . . . . .
15  Iodine  . . . . . . . . . . . . . . . . . . . . . . . .
16  Zinc  . . . . . . . . . . . . . . . . . . . . . . . . . .
17  Selenium  . . . . . . . . . . . . . . . . . . . . . .
18  Copper  . . . . . . . . . . . . . . . . . . . . . . .
19  Chromium  . . . . . . . . . . . . . . . . . . . . .
20  Magnesium  . . . . . . . . . . . . . . . . . . . .
21  Cod liver oil  . . . . . . . . . . . . . . . . . . .
22  Omega-3 fatty acid  . . . . . . . . . . . . .
13–16 17–20 21–24 25–28 29+
4-6 1-3
Daily times times
a week a week

VAppendix
Dietary habits in MoBa (FFQ) 
Page 4 of the FFQ returned around gestational week 18 until April 2004. The 
complete questionnaire can be found at: www.fhi.no/artikler/?id=51491. 
 4 
5. Do you use butter/ margarine with your sandwiches?  
 
                                                Yes                                     No (go to question 8) 
 
6.   If you use butter /margarine, on how many sandwiches on average and what kind do you use?  
                                          Number of slices 
 
Type of butter/ margarine 
                            per day 
 13+    9-12    8     7      6      5     4     3     2     1 
 or      per week 
 5-6   3-4   1-2    0 
1. Butter/ /Bremyk                                                   
2. Hard margarine (Per, Melange)                                                  
3. “Brelett”                                                  
4. Soft margarine (Soft, Vita, Olivero etc.)                                                  
5. Light margarine (Soft light, Vita lett etc.)                                                  
 
 
7. How much butter/ margarine do you use on you sandwiches? 
 
              Plenty        Medium            Minimum 
                                       
 
 
Cheese/ meat cold cuts/ fish/ spreads   
8.   How often do you have the following food items on your sandwiches?   
 Number of slices with this food item 
 
Cheese 
                 per day 
 6+      5      4       3      2      1   
or    per week 
 5-6     3-4     1-2 
or   per month 
   3       2      1      0 
1. Whey cheese goat milk, regular                                                        
2. Whey cheese low fat, spread goat milk                                                        
3. Hard cheese, cream cheese                                                        
4. Hard cheese, cream cheese, low fat                                                       
5. Blue cheese (Camembert, Norzola etc.)                                                       
6. Other kinds of cheese                                                       
 
Fish 
 
  
7. Roe spread                                                       
8. Mackerel/sardine in tomato sauce                                                         
9. Sardine in oil                                                       
10. Smoked salmon/trout/mackerel                                                       
11. Herring, pickled                                                       
12. Shrimp, Northern                                                       
13. Crab                                                       
14. Tuna                                                       
15. Svolværpostei (spread of fish liver/roe)                                                       
16. Other kinds of fish                                                       
 
Meat 
   
17. Low fat cold cuts (ham, roast beef etc.)                                                       
18. Medium fat cold cuts of lamb, calf etc.                                                        
19. Salami, Swedish sausage etc.                                                       
20. Cold cuts of turkey, chicken                                                       
21. Liver paste                                                       
22. Other kinds of meat                                                       

VIAppendix
Dietary supplements in MoBa (FFQ) 
Page 14 of the FFQ returned around gestational week 18 until April 2004. The 
complete
 
questionnaire can be found at: www.fhi.no/artikler/?id=51491. 
 14 
 
 
Supplements 
 
39.  Do you use, or have you used supplements during this pregnancy?        Yes             No 
 
40.  If yes, we ask you to name and quantify the supplements you have used/are using  
        (ts = teaspoon, bs = dessert spoon, ss = tablespoon) 
 
 Liquid supplements 
                       Times per week 
  7       6      5     4       3      2      1   <1     0 
Amount  
 1 ts   1bs    1ss 
1. Cod liver oil                                                      
2. Omega-3 cod liver oil                                                      
3. Sanasol                                                         
4. Biovit                                                      
5. Liquid iron mixture (Floradix etc.)                                                      
 
Other liquid supplements 
   
6. Name:                                                      
7.Corporation:   
8. Name:                                                      
9.Corporation:   
 
 
Capsules/tablets 
                   
                      Times per week 
  7       6      5     4       3      2      1   <1     0 
 
Number(s) at a 
time 
  1    2     3     4+ 
10. Cod liver capsules                                                  
11. Cod liver capsules without A and D-    
vitamins 
                                                 
12. Vitaplex                                                  
13. Kostpluss/nyco plus multi                                                  
14. Nyco plus folic acid 0,4 mg                                                  
15.Spektro (Solaray)                                                  
16. Hemofer                                                  
17. Duroferon duretter                                                  
Other supplements    
 18. Name:                                                  
 19. Corporation:   
 20. Name:                                                  
 21. Corporation:   
 22. Name:                                                  
 23. Corporation:   
 24. Name:                                                  
 25. Corporation:   
 
Please remember to fill out the date on page 2! 
 
 
Thank you for your time and help! 

VIIAppendix
Vitamin supplement use in MBRN 
Section of the MBRN form filled out during hospitalization at the time of birth. 
 
 
  
 
The complete notification form is shown in Appendix 1. 
 
 

VIIIAppendix
Additional table 
Covariates and confounders included in papers 1 through 4. 
  Paper 
Data source Categorization 1 2 3 4 
      
MBRN       
   Year of delivery Years Yes Yes Yes Yes 
   Maternal age <25, 25-34, 35 years Yes Yes Yes Yes 
   Marital status Married, cohabitation, single Yes Yes Yes Yes 
   Parity 0, 1, 2, 3 previous births Yes Yes Yes Yes 
   Maternal diseasesa No, yes (before pregnancy) Yes  Yes Yes 
   Previous stillbirths  0, 1, 2 previous births Yes   Yes 
   Maternal smokingb  No, yes (daily or occasional)   Yes Yes 
   In-vitro fertilization No, yes    Yes 
   Medication use No, yes (during pregnancy)    Yes 
      
MoBa       
   Maternal income  Low, medium, high (NOK) Yes    
   Maternal education 0-9, 10-12, 13 years Yes Yes   
   Paternal education 0-9, 10-12, 13 years Yes    
   Prepregnancy BMI <18.5, 18.5-24.9, 25-29.9, 30 kg/m2 Yesc Yes   
   Pregnancy planning No, yes Yes    
   In-vitro fertilization No, yes Yes    
   Ovarian stimulation No, yes Yes    
   Maternal smoking No, yes (daily or occasional) Yesd Yese   
   Total energy intake Quartiles in μg/day  Yes   
a Up to 8 diseases, including epilepsy, chronic hypertension, and pregestational diabetes. 
b Any smoking during pregnancy (paper 3) or smoking at end of pregnancy (paper 4). 
c The 2 first categories were pooled, i.e. prepregnancy BMI <25.0 kg/m2 (paper 1). 
d
 Smoking during pregnancy was assessed by the baseline and the follow-up 
questionnaires. 
e Smoking during pregnancy was assessed by plasma cotinine around gestational week 18 
(paper 2). 
 

